Biological analysis of the in-vitro effects of homologous recombination inhibition and its use in cancer treatment through synthetic lethality by Balboni, Andrea <1992>
 
 
Alma Mater Studiorum – Università di Bologna 
 
 
DOTTORATO DI RICERCA IN 
 
SCIENZE BIOTECNOLOGICHE, BIOCOMPUTAZIONALI, 
FARMACEUTICHE E FARMACOLOGICHE 
Ciclo XXXIII 
 
Settore Concorsuale: 03/D1 
 





BIOLOGICAL ANALYSIS OF THE IN-VITRO EFFECTS OF HOMOLOGOUS 
RECOMBINATION INHIBITION AND ITS USE IN CANCER TREATMENT 










Coordinatore Dottorato                Supervisore 
Prof.ssa Maria Laura Bolognesi               Prof. Andrea Cavalli  
 
                                                                                    Co-Supervisore 
                                                                                    Prof.ssa Giuseppina di Stefano 
                          
 

































2.1. SYNTHETIC LETHALITY………………………………….………07 
2.1.1 Cancer overview………………………………………….…….07 
2.1.2 Use of inhibiting strategies for Cancer treatments…………..07 
2.1.3 The Synthetic Lethality…………………………………….….08 
 
2.2. PARP INHIBITORS………………………………………………….10 
2.2.1 Poly (ADP-ribose) Polymerase…………....…………………....10 
2.2.2 Olaparib………………………………….……………………....11 
 
2.3. DOUBLE STRAND DAMAGE REPAIR MECHANISMS………...14 
2.3.1 Double strand breaks overview………………………………....14 
2.3.2Non-homologous End Joining Repair…......................................15 
2.3.3Homologous Recombination…………………………………….16 
 
2.4. PROJECT A: INHIBITION OF HR ACTIVITY THROUGH THE 
USE OF RAD51-BRCA2 DISRUPTORS…..………………………..17 
2.4.1 BRCA2 structure………………………………………………...17 
2.4.2 RAD51 Structure……..………………………………………….18 
2.4.3 Interaction between BRC4 and Zone I and Zone II of 
RAD51………………………………………………………………….19 
 
     2.5.    PROJECT B: INHIBITION OF HR ACTIVITY THROUGH THE  
               USE OF LDH INHIBITORS………………………………………….20 
               2.5.1 Cancer: a metabolic disease……………………………………..20 




               2.5.2 Correlation between LDH activity and DNA repair  
                        mechanisms………………………………………………………24 
 
3) SPECIFIC AIMS………………………………………………………….25 
 
4) MATERIALS & METHODS………………………………….……….27 
4.1 Cell culture……………………………………………………………….27 
 
4.2 Viability Assay…………………………………………………………...27 
        4.2.1 CellTiter-Glo ATP Assay………………………………………...27 
        4.2.2 Neutral Red Assay………………………………………………..27 
 
4.3 Lethality Assays………………………………………………………….28 
         4.3.1 CellToxTM Green Cytotoxicity Assay…………………………...28 
         4.3.2 Vital dyes assay…………………………………………………..28 
 
4.4 Homologous Recombination Assay……………………………………..28 
 
4.5 Western Blot analysis…………………………………………………....29 
 
4.6 Micronuclei visualization………………………………………………..29 
 
4.7 Immunofluorescence experiments……………………………………...30 
 
4.8 Real-time PCR……………………………………………………….…..31 
 
4.9 Measurements of lactate levels…………………………………………32 
 
4.10 Statistical analysis……………………………………………………...32 
 






5) RESULTS & DISCUSSION……………….………………………..…..35 
5.1 PROJECT A: INHIBITION OF HR ACTIVITY THROUGH THE 
USE OF RAD51-BRCA2 DISRUPTORS………….………..………………35 
         5.1.1 ZONE I RAD51-BRCA2 DISRUPTORS…….………………....35 
              5.1.1.1 Preliminary selection of Zone I disruptors………...……...35 
              5.1.1.2 Western Blot analysis on γ-H2AX bands……….…..….….38 
              5.1.1.3 Lethality Assay on BxPC-3 and Capan-1 cells…..……...…38 
              5.1.1.4 Project A final discussion (Zone I)……….….…..………....39 
 
         5.1.2 ZONE II RAD51-BRCA2 DISRUPTORS……….…..................41 
               5.1.2.1 Preliminary selection of Zone II disruptors………….…..41 
               5.1.2.2 Immunohistochemical staining of RAD51 and γ-H2AX 
                           nuclear foci…………………………………..………….….43 
               5.1.2.3 Micronuclei visualization in BxPC3 treated cells……......44 
               5.1.2.4 Cell death evaluation in ARN 24089+OLA association....45 
               5.1.2.5 Viability Assay with Capan-1 and HK-2….……..……….47 
               5.1.2.6 Project A final discussion (Zone II)………………….…...49 
 
5.2 PROJECT B: INHIBITION OF HR ACTIVITY THROUGH THE 
USE OF LDH INHIBITORS………………………………………………..50 
         5.2.1 Metabolic characterization of cell cultures……………...…......50 
         5.2.2 Cellular viability Assessed by CellTiter-Glo and Neutral  
                  Red……………………………………………………...…….......50 
         5.2.3 Study of homologous recombination in LDH-inhibited cells…52 
                5.2.3.1 Expression level of HR-related genes………………...….52 
                5.2.3.2 Evaluation of plasmid recombination in OXA treated  
                            Cells……………………………………….…...…………...53 
                5.2.3.3 γ-H2AX immunoblotting in OXA/OLA treated cells…...55 
                5.2.3.4 Evaluation of RAD51 nuclear translocation upon CPL 
                            treatment……………………………………………...…...56 
         5.2.4 Cell viability and death in combination experiments with  
                  OXA and OLA…………………………………………...……....57 
         5.2.5 Cell death evaluation in combination experiments with  
                  OXA and OLA……………………………………...……………58 
 
 



































Synthetic lethality represents an anticancer strategy that targets tumor specific gene defects. One 
of the most studied application is the use of PARP inhibitors (e.g., olaparib) in BRCA1/2-less 
cancer cells. In BRCA2-defective tumors, olaparib (OLA) inhibits DNA single-strand break 
repair, while BRCA2 mutations hamper homologous recombination (HR) repair. The 
simultaneous impairment of those pathways leads BRCA-less cells to death by synthetic 
lethality.  
The projects described in this thesis were aimed at extending the use of OLA in cancer cells that 
do not carry a mutation in BRCA2 by combining this drug with compounds that could mimic a 
BRCA-less environment via HR inhibition. Contrary to the conventional use of OLA in cancer 
treatment, this “fully small-molecule induced synthetic lethality” could be applied to a higher 
variety of cancer types. 
We demonstrated the effectiveness of our “fully small-molecule induced synthetic lethality” by 
using two different approaches. 
In the direct approach (Project A), we identified a series of neo-synthesized compounds (named 
RAD51-BRCA2 disruptors) that mimic BRCA2 mutations by disrupting the RAD51-BRCA2 
interaction and thus the HR pathway. Compound ARN 24089 showed the most promising results 
in our experiments. ARN 24089 inhibited HR in human pancreatic adenocarcinoma cell line and 
triggered synthetic lethality by synergizing with OLA. Interestingly, the observed synthetic 
lethality was triggered by tackling two biochemically different mechanisms: enzyme inhibition 
(PARP) and protein-protein disruption (RAD51-BRCA2). This highlights how complex and 
diverse mechanisms of action can synergistically contribute to the same physiological and, in 
turn, pharmacological activity. 
In the indirect approach (Project B), we inhibited HR by interfering with the cellular metabolism 
through inhibition of LDH activity. Various studies hint a possible connection between the 
activity of this enzyme and the efficiency of DNA repair pathways. The obtained data suggest an 
LDH-mediated control on HR that can be exerted by regulating  either the energy supply needed 
to this repair mechanism or the expression level of genes involved in DNA repair. LDH 
inhibition also succeeded in increasing the efficiency of OLA in BRCA-proficient cell lines. 
Although preliminary, these results highlight a complex relationship between metabolic reactions 
and the control of DNA integrity. 
Both the described projects proved the possibility to widen the use of OLA in BRCA-competent 
and OLA-resistant cancers, making this “fully small-molecule-induced synthetic lethality” an 
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- DDR: DNA-damage repair 
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2.1 SYNTHETIC LETHALITY 
 
      2.1.1    Cancer overview 
 
Cancer is globally the second leading cause of death, and is responsible for an estimated 9.6 
million deaths in 2018. The name Cancer refers to a class of diseases in which abnormal cells 
divide without control and can invade nearby tissues. Cancer cells can also spread to other 
parts of the body through the blood and lymph systems. There are several main types of 
cancer. Carcinoma is a cancer that originates from epithelial tissues. Sarcoma is a cancer that 
begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. 
Leukemia is a cancer that starts in blood-forming tissue, such as the bone marrow, and causes 
large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and 
multiple myeloma are cancers that begin in the cells of the immune system [1]. 
In 2018 the most common causes of cancer death, worldwide, were Lung cancer (1.76 
million deaths), Colorectal (862.000 deaths), Stomach (783.000 deaths), Liver (782.000 
deaths) and Breast (627.000 deaths). Every cancer type requires a specific treatment regimen 
that encompasses one or more modalities such as surgery, radiotherapy, and chemotherapy 
[2].  
 
      2.1.2    Use of inhibiting strategies for Cancer treatments 
 
Even though some cancers now have a higher survivability rate, there is still much to do and 
the discovery of new anticancer therapies is a critical point in the world of clinical research; 
in the past decades, researchers all over the world focused on developing new therapies 
centered on target genes or proteins that are critical for the cancer cells. 
Some therapies revolve around the activities of inhibiting molecules such as STI571, a 
tyrosine kinase inhibitor used in the treatment of Chronic Myeloid Leukemia (CML): CML is 
a malignant clonal disorder of hematopoietic stem cells that results in increases in myeloid 
cells and marked myeloid hyperplasia in the bone marrow [3]. CML is characterized by a 
balanced translocation between chromosome 9 and 22 that leads to the formation of 
BCR/ABL, a chimeric protein characterized by an unregulated tyrosine kinase activity [4]. 
Since the activity of BRC/ABL is essential for CML cells, by administering them a tyrosine 
kinase inhibitor like STI571 a cytogenetic remission can be observed that can lead to an 
increase in cancer cell death and in an increase in the patient survival [5]. 
Against other types of cancers, the therapies involve the use of monoclonal antibodies; a 
perfect example is the use of Bevacizumab for the treatment of Renal Cell Carcinoma. This 
carcinoma presents an increase in the transcription of several hypoxia-inducible genes, one of 




that inhibits dendritic cell maturation and tumor cell apoptosis and stimulates tumor 
angiogenesis [6]. Administering interferon Alfa along with Bevacizumab, a humanized 
monoclonal antibody that inhibits VEGF, produces significant and clinically meaningful 
improvements in progression-free survival and overall response rates. These findings indicate 
that the bevacizumab/interferon Alfa association is a promising option for first-line treatment 
for patients with metastatic renal cell carcinoma. [7] 
Those targeted therapies, however, have some limitations since it is not always possible to 
target a protein or a gene that plays a central role in a cellular pathway. Side effects arising 
by on- and off-targets are always an issue because the inhibitors could target also the healthy 
cells. In order to perfect these precision therapies, many researchers have started to focus 
their attention on “synthetic lethality”. 
 
2.1.3 Synthetic lethality 
 
The concept of synthetic lethality originates from studies in drosophila model systems in 
which a combination of mutations in two or more separate genes leads to cell death, while 
the single mutated genes do not affect the viability of the cell [8] [Figure 2.1]. These tumor-
specific genetic defects lead to the use of targeted agents that induce the death of tumor cells 
while sparing normal cells. Oncogenic drivers such as mutated KRAS and MYC can be 
targeted with synthetic-lethality approaches.  
Oncogenic mutations in RAS genes are very common in human cancer and its removal from 
tumor cell lines resulted in reversal of cell transformation [9]. However, a selective inhibition 
of that protein using drugs has so far proven to be impossible. Carrying out a large-scale loss-
of-function screen, researchers discovered that RAS mutated cell lines were highly dependent 
on the transcription factor GATA2 and the DNA replication initiation regulator CDC6. These 
same cells showed synthetic lethality with topoisomerase inhibition. Combination targeting 
of these functions caused improved killing of KRAS mutant cells relative to wild-type cells. 
[10] 
MYC is also one of the most commonly deregulated oncogenes in human cancer, yet 
therapies directly targeting MYC hyper-activation are not presently available in the clinic. 
The evolutionarily conserved function of MYC in modulating protein synthesis control is 
critical for its oncogenic program [11]. Therefore, inhibiting enhanced protein synthesis 
represents a highly relevant strategy for the treatment of MYC-dependent human cancers. 
Researchers found, using a pharmacogenetic approach, that mTOR-dependent 
phosphorylation of 4EBP1 (a regulator of protein synthesis control) is required for cancer cell 
survival in MYC-dependent tumor initiation and maintenance. They also discovered that a 
clinical mTOR active site inhibitor, which is capable of blocking mTOR-dependent 4EBP1 








Figure 2.1. (A) Gene A and Gene B are both without mutations and the cell is alive. (B) One of the genes is 
mutated while the other is still without mutations; this situation does not impair cellular viability. (C) Both 
genes are mutated, leading to cell death through synthetic lethality. 
 
Synthetic lethality can also be applied in patients suffering from Myelodysplastic Syndrome 
(MDS) with a chromosome 5q deletion (del[5q]), which is the most common chromosomal 
abnormality detected in MDS with an overall case prevalence of 10%–15%. This deletion 
leads to haploinsufficiency of genes encoded within the commonly deleted region at 5q31 to 
5q32, including the ribosomal subunit 14 gene (RPS14) [13].  
In December 2005, the United States Food and Drug Administration (FDA) approved 
lenalidomide (Revlimid; Celgene Corporation) for the treatment of transfusion-dependent, 
lower-risk patients with del[5q] MDS. Suppression of del[5q] clones by lenalidomide arises 
mainly from inhibition of two phosphatases that are co-regulators of the G2–M checkpoint: 
cell division cycle 25 homologue C (CDC25C) and protein phosphatase 2A (PP2A) catalytic 
subunit alpha (PP2Aca). Allelic haploinsufficiency of both phosphatases leads to enhanced 
sensitivity to lenalidomide; this portrays the principle of synthetic lethality in practice, 
whereas overexpression of PP2A is associated with secondary resistance to this agent [14]. 
Synthetic lethality can also be useful in targeting tumors with a mutated TP53 gene. It is 
difficult to target mutant p53 protein or restore functional p53 activity directly in a manner 
that translates readily into a clinical benefit. For this reason, identification of genes that show 
synthetic lethality with it is an area of active investigation. For instance, the stress-activated 
p38 mitogen-activated protein kinase MAPKAP kinase 2 (MK2) appears to be essential for 
survival of p53-deficient non–small-cell lung cancer (NSCLC) cells in response to 
chemotherapy. A study showed that, in cells lacking functional p53, MK2 could induce a 
cell-cycle checkpoint after genotoxic stress [15]. This occurs through modulation of the 
RNA-binding protein hnRNPA0, promoting the association of hnRNPA0 with the cyclin-
dependent kinase inhibitor GADD45A, and up-regulation of microRNA miR-34c, which can 
indirectly promote S-phase arrest. Deficiency of MK2 in autochthonous p53-deficient murine 
NSCLC models leads to augmented cisplatin sensitization.  
Furthermore, ATM suppression in p53-deficient tumors can directly sensitize tumors to 
chemotherapy; in contrast, ATM suppression in models of p53-proficient tumors can induce 
chemoresistance [16]. In addition, a study in models of cervical cancer has shown that 




survival by inducing autophagy (with SGK2 depletion) or apoptosis (with PAK3 depletion). 
Therefore, potential approaches exist for targeting these proteins in tumors with Tp53 
mutations [17]. 
Our project revolves around another synthetic lethality gene pair: BRCA2, involved in 
double strand repair, and PARP, involved in single strand repair. Several studies revealed 
that dysfunction of BRCA1 and BRCA2 dramatically sensitized cells to poly (adenosine 
diphosphate [ADP]–ribose) polymerase (PARP) inhibitors because of associated defective 
homologous recombination and the inability to mount efficient DNA repair [18]. 
 
2.2 PARP INHIBITORS 
 
2.2.1 Poly (ADP-ribose) Polymerase 
 
Poly (ADP-ribose) polymerase (PARP) is responsible for post-translational modification of 
proteins in response to numerous endogenous and environmental genotoxic agents. PARP 
and poly (ADP-ribosyl)ation are involved in the regulation of many cellular processes such 
as DNA repair, cell death, chromatin functions and genomic stability. Activation of PARP is 
one of the early DNA damage responses, among other DNA sensing molecules, such as 
DNA-PK, ATM and p53 [19].  
PARP presents two distinct regions: an amino-terminal DNA-binding domain with two zinc-
fingers (28-30 residues), essential for binding to DNA breaks, and a carboxy-terminal 
catalytic domain. Experimental data showed that PARP tends to preferentially bind at DNA 
breaks, covering 7-8 residues at each side of the breaks [20]. The spacing between the amino 
acids in the zinc-fingers is unusual, but similar arrangements have been observed in the 
amino-terminal region of human DNA ligase III and in the carboxy-terminal region of DNA 
polymerase ɛ; this structure is believed to be fundamental for preferring the binding at DNA 
breaks sites [21-22]. 
The catalytic domain shows homologies to NAD-binding sites observed in other enzymes; 
this domain requires PARP to be bound to the DNA in order to catalyze an efficient polymer 
synthesis. Interestingly, the strand interruptions regularly occurring during DNA replication 
do not trigger Poly (ADP-ribosyl)ation, probably because the replisomes that protect the 
termini of Okazaki fragments prevent the access of PARP and other enzymes that are not 
directly involved in the replication process [23]. 
The process of Poly (ADP-ribosyl)ation is catalyzed primarily by poly(ADP-ribose) 
polymerase-1 (PARP1), which is the most abundant of the 18 different PARP isoforms and 
accounts for more than 90% of the catalytic activity of PARP in the cell nucleus. Upon 
detection of a DNA strand break, PARP1 binds to the DNA, cleaves nicotinamide adenine 
dinucleotide (NAD) between nicotinamide and ADP-ribose and then modifies the DNA 
nuclear acceptor proteins (PARP included) by formation of a bond between the proteins and 




DNA-repairing enzymes and DNA base repair [24]. Several Glu residues, situated between 
the DNA binding domain and the Catalytic domain, serve as anchor points for Poly (ADP-
ribose) polymer synthesis: these polymers can form branches and become up to several 
hundred residues long. After the DNA has been repaired, these branches are slowly degraded 
by the Poly (ADP-ribose) glycohydrolase enzyme (pARG), liberating free ADP-ribose 
monomers [25]. 
Studies have shown that the auto-modified PARP differs from the original enzyme in being 
unable to bind to DNA. This can be explained by the fact that ADP-ribose is strongly 
negatively charged and charge repulsion between the branches and the DNA leads the release 
of the auto-modified enzyme. This detachment shuts down ulterior branch synthesis, which 
are then removed by the action of pARG, and this grants PARP the ability to shuttle on and 
off damaged DNA. Since pARG acts slowly it creates a useful window in which DNA repair 
can occur before PARP reattaches itself to the lesion [26]. 
Whereas activation of PARP by mild genotoxic stimuli may facilitate DNA repair and cell 
survival, irreparable DNA damage triggers apoptotic or necrotic cell death. In apoptosis, 
early PARP activation may assist the apoptotic cascade by stabilizing p53, by mediating the 
translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus or by 
inhibiting early activation of DNases. In most severe oxidative stress situations, excessive 
DNA damage causes over activation of PARP, which incapacitates the apoptotic machinery 





Poly (ADP-ribose) polymerase (PARP) inhibitors have been studied as potential cancer 
therapeutics in breast and ovarian cancers. PARP inhibitors have several documented 
mechanisms of action, including the inhibition of base excision repair (via blockade of 
enzymatic function) as well as trapping of PARP upon the DNA [28]. Tumors in which there 
is an apparent defect in homologous DNA repair (and thus defect in repair of double-stranded 
breaks) seem to be susceptible to PARP inhibitor therapy. These include tumors associated 
with germline or somatic mutations in BRCA1 and BRCA2 (BRCA1/2) [29] [Figure 2.2]. 
PARP inhibitors target and bind the catalytic domain of the protein, preventing the formation 
of the ADP-ribose branches and the subsequent detachment of the protein from the damaged 
area. By blocking PARP on the DNA, these small molecules can interfere with the whole 
repair mechanism. 
In 2011 encouraging results of Phase II clinical trials involving a PARP inhibitor called 
Iniparib were published in peer-reviewed journals. In one of the studies, which included 
patients with triple-negative breast cancer, the inclusion of Iniparib to chemotherapy 
improved the clinical benefit and survival of patients without significantly increased toxic 




benefit from 34% to 56% and the rate of overall response from 32% to 52%. The addition of 
Iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months 
and the median overall survival from 7.7 months to 12.3 months. [30]. 
 
 
Figure 2.2. (A) PARP inhibitor prevent PARP from being located on SSB. In normal cells SSB are converted to 
DSB and repaired through homologous recombination. (B) In BRCA-mutated cells DSB is not repaired 
effectively, leading to cell death.  
 
One of the most famous PARP inhibitors available is Olaparib (Lynparza™). Olaparib 
(OLA) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor that has been 









This molecule acts on PARP-1, PARP-2 and PARP-3 and inhibits them, preventing the 
formation of the ADP-ribose branches thus increasing the formation of PARP-DNA 
complexes, disrupting cellular homeostasis and causing cell death [31].  
OLA has been indicated for the treatment of different types of cancers [32]: 
- Ovarian Cancer: for the maintenance treatment of adult patients with deleterious or 
suspected deleterious germline or somatic BRCA-mutated advanced cancer who are in 
complete or partial response to first-line platinum-based chemotherapy. OLA is used also 
for the treatment of adult patients with deleterious or suspected deleterious germline 
BRCA mutated (gBRCAm) advanced ovarian cancer who have been treated with three or 
more prior lines of chemotherapy. 
- Breast Cancer: for the treatment of adult patients with deleterious or suspected 
deleterious gBRCAm, HER2 negative metastatic breast cancer who have been treated 
with chemotherapy in the neo-adjuvant, adjuvant or metastatic setting. 
- Pancreatic Cancer: for the maintenance treatment of adult patients with deleterious or 
suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has 
not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. 
- Prostate Cancer: for the treatment of adult patients with deleterious or suspected 
deleterious germline or somatic homologous recombination repair (HRR) gene-mutated 
metastatic castration-resistant prostate cancer (mCRPC) who have progressed following 
prior treatment with enzalutamide or abiraterone. 
OLA, similarly to other PARP inhibitors, is extremely efficient in tumors with compromised 
homologous recombination (HR) activity but has low or no effect on tumors where those 
specific alterations are missing. The aim of our project is to enhance the effect of OLA in 
BRCA-proficient tumors by recreating a BRCA-less environment in our cell lines through 
compounds that could impair the efficiency of the HR mechanism [Figure 2.4]. 
 
Figure 2.4. (A) OLA inhibits PARP activity in a BRCA-deficient cell, leading to death by synthetic lethality. (B) 





2.3 DOUBLE STRAND DAMAGE REPAIR MECHANISMS 
 
2.3.1 Double-strand breaks overview 
 
Double-strand DNA breaks (DSBs) are common events in eukaryotic cells. There are an 
estimated ten DSBs per day per cell, based on metaphase chromosome and chromatid breaks 
in early passage primary human or mouse fibroblasts [33]. Major pathologic causes of 
double-strand breaks in wild type cells are caused by replication across a nick, giving rise to 
chromatid breaks during S phase. Reactive Oxygen Species (ROS) [34], Ionizing Radiations 
[35] and inadvertent action by nuclear enzymes on DNA (e.g., Topoisomerase activity) [36] 
can cause DSBs as well. 
 Cells use two major pathways for repairing DSBs: homologous recombination (HR) and 
non-homologous DNA end joining (NHEJ). NHEJ is the most common pathway used by 
cells for DSBs repair, while HR is mainly used during S-phase and G2-phase [Figure 2.5].  
 
 
Figure 2.5. Physiologic and pathologic causes of double-strand breaks in mammalian somatic cells are listed 
at the top. During S and G2 of the cell cycle, homology-directed repair is common because the two sister 
chromatids are in close proximity, providing a nearby homology donor. At any time in the cell cycle, double-
strand breaks can be repaired by non-homologous DNA end joining (NHEJ). Proteins involved in the repair 
pathways are also listed.  
 
It is not fully clear how the pathways are selected, but it might be correlated to the distance 
between the damaged sequence and the homologous one. During S and G2 the sister 
chromatids are closer, thus HR is more likely to happen, while outside of those phases NHEJ 




distant homologous sequences could lead to chromosomal abnormalities through random 
recombination of repeated DNA sequences that are present all across the genome [38]. 
 
2.3.2 Non-homologous End Joining Repair 
 
NHEJ is distinctive for the flexibility of the nuclease, polymerase, and ligase activities that 
are used. This flexibility permits NHEJ to function on the wide range of possible substrate 
configurations that can arise when double-strand breaks occur. When NHEJ takes place, the 
first protein that binds DNA is the KU heterodimer (KU70/KU80), thanks to its abundance in 
the nucleus and its high affinity for duplex DNA ends [39]. The KU-DNA complex serve as 
a node at which NHEJ’s nucleases, polymerases and ligases can dock: this recruitment is 
very flexible and each protein can dock at any order. Other proteins involved in NHEJ are the 
nuclease complex Artemis-DNA PKcs (DNA-dependent Protein Kinase Catalytic Subunit), 
the two polymerases µ and λ and the ligases XRCC4 and DNA ligase IV [40]. 
The complex Artemis-DNA PKcs, upon coming into contact with the KU-DNA complex, 
phosphorylate themselves and start their endonuclease activity at the overhangs, but also at 
other single/double strand structures such as DNA hairpins [41]. 
Upon fortuitous pairing of the overhangs, the two polymerases are recruited and start to 
resynthesize the missing parts of the double strand filament; during the synthesis some 
template slippage could occur, which would lead to the formation of direct repeats. The 
evolutionary advantage of this becomes clear when considering a DSB in which there is no 
terminal microhomology between the two DNA ends. Random addition has the benefit of 
potentially generating one or two nucleotides of terminal microhomology, permitting more 
efficient annealing of the ends and thereby facilitating NHEJ [42]. 
Lastly, the ligases are recruited in order to complete the repair process and the XRCC4-DNA 
ligase IV complex shows a remarkable degree of flexibility. First, XRCC4-DNA ligase IV 
can ligate one strand independent of the other strand. Second, XRCC4-DNA ligase IV can 
ligate across gaps of even several nucleotides. Third, when KU is present, XRCC4-DNA 
ligase IV can ligate some incompatible DNA ends that have short overhangs. All of these 
aspects of the flexibility contribute to the range of DNA end configurations that XRCC4-
DNA ligase IV can handle in its challenging role as the only ligase optimally suited for the 
repair of DSBs [43]. 
The NHEJ complex acts on both edges of the DNA damaged area and thanks to the high 
versatility of its pathway can manage to restore its integrity. However, since this process does 
not utilize a homologous sequence, some bases can be lost during the repair process and can 
lead to the accumulation of randomly located mutations over time in the genome of each 







2.3.3 Homologous recombination 
 
HR provides high fidelity, template-dependent repair or tolerance of complex DNA damages 
including DNA gaps, DNA double-stranded breaks (DSBs), and DNA interstrand crosslinks 
(ICLs). In addition to its role in preserving the genome, HR plays a prominent role in 
faithfully duplicating the genome by providing critical support for DNA replication and 
telomere maintenance [44]. 
The central reaction of HR is homology search and DNA strand invasion by the RAD51-
ssDNA filament, positioning the invading 3′-end on a template duplex DNA to initiate repair 
synthesis. In the nuclear environment the heterotrimeric ssDNA-binding protein RPA, which 
displays higher affinity and specificity for ssDNA than Rad51, initially binds ssDNA. Hence, 
in vivo RAD51 must assemble to form the presynaptic filament on RPA-coated ssDNA [45]. 
RPA inhibits nucleation of the RAD51 filament on ssDNA, but stimulates recombination by 
eliminating secondary structure in ssDNA and by binding to the displaced strand of the D-
loop [46].  
The tumor suppressor BRCA2 is a mediator of the core mechanism of homologous 
recombination. Heterozygous mutations in BRCA2 predispose to breast, ovarian as well as 
other tumor types. Bi-allelic loss of BRCA2 function causes Fanconi Anemia, a rare genetic 
disease resulting in impaired response to DNA damage [47]. BRCA2 contains eight 
conserved sequence motifs called BRC repeats, which are the primary RAD51 binding sites 
[48].  
After the RAD51- BRCA2 complex is formed, RAD51 coats single-stranded DNA substrates 
to form a helical nucleoprotein filament, which can invade duplex DNA, and pair with 
homologous nucleotides to initiate the strand exchange reactions that culminate in genetic 
recombination. The interaction between BRCA2 and RAD51 is critical for the biological 






Figure 2.6. After DNA is damaged, BRCA2 binds RAD51 with BRC 1-4, binds to ssDNA and recruits other 
RAD51 units. RAD51 localizes to the damaged filament by interacting with BRC 5-8, starts to form a RAD51 
filament and displaces RPA in order to begin the strand invasion and the subsequently the repair of DNA. 
 
2.4 PROJECT A: INHIBITION OF HOMOLOGOUS RECOMBINATION ACTIVITY 
THROUGH THE USE OF RAD51-BRCA2 DISRUPTORS 
 
2.4.1 BRCA2 structure 
 
BRCA2 is a 3418-aminoacid long protein that is highly expressed during meiosis and 
localizes to the nucleus during the S phase.  Crystallographic studies revealed that BRCA2 
possesses both a DNA-binding domain (DBD), with unique structural features for binding 
ssDNA and dsDNA [49], and eight conserved sequence motifs—the BRC repeats—of about 
30 amino acids each positioned between residues 990 and 2100 (in human BRCA2). 
Although the overall sequence similarity among BRCA2 orthologues is limited, the BRC 
repeats in different species are well conserved, suggesting that they are essential to the 




When expressed in vitro, six of the eight BRC repeats in BRCA2 can interact directly with 
recombinant RAD51. BRC3 and BRC4 encoded in human BRCA2 are particularly efficient 
at RAD51 binding, whereas BRC5 and BRC6 are not [51]. 
The binding of BRC4 with RAD51 is maintained by a series of hydrophilic and hydrophobic 
interactions conferred by a hairpin structure and a short linker that binds RAD51 in two 
different loci: the N-terminal domain and the nucleotide-binding core. The BRC4 sequence 
mimics that of RAD51’s oligomerization motifs thus preventing its incorporation into 
RAD51 nucleoprotein filaments [52].  
The presence of both the BRC repeats and the DBD on BRCA2 indicates that the protein can 
bind both RAD51 and the DNA and can deliver RAD51 to the sites of DNA breaks. A study 
revealed the existence of two categories of BRC repeats that display unique functional 
characteristics. One group, comprising BRC1, -2, -3, and -4, binds to free RAD51 with high 
affinity and reduces its ATPase activity. The second group, comprising BRC5, -6, -7, and -8, 
binds to free RAD51 with low affinity but binds to the RAD51-ssDNA filament with high 
affinity and does not reduce its ATPase activity. Thus, through different mechanisms, both 
types of BRC repeats bind to and stabilize the RAD51 nucleoprotein filament on ssDNA. 
These two groups of BRC repeats have differentially evolved to ensure efficient formation of 
a nascent RAD51 filament on ssDNA by promoting its nucleation and growth, respectively 
[53]. 
 
2.4.2 RAD51 structure 
 
The RAD51 protein is the eukaryotic homolog of the prokaryotic RecA, and is the central 
recombinase in eukaryotes [54]. RAD51-mediated strand exchange proceeds via several 
steps. First, a single-stranded DNA tail that is the result of processing by other factors is 
coated by ATP-bound RAD51 to yield a nucleoprotein filament. This filament then searches 
for a homologous sequence within duplex DNA, and catalyzes the exchange of strands 
between the single-stranded and double-stranded DNA (ssDNA and dsDNA) substrates. At 
the end of this process, the original broken end of the damaged DNA filament is aligned with 
an appropriate matching sequence in an intact duplex, and is further processed by other 
enzymes [55]. 
RAD51 possesses an ATPase domain that is structurally similar to the ATPase domains of 
helicases and of the F1 ATPase [56] and an N-terminal domain used for the interactions with 
DNA [57]. Electron microscopy studies have shown that RAD51 oligomerizes and forms 
helical filaments in which the DNA lies close to the filament axis [58]. As mentioned before, 








2.4.3 Interaction between BRC4 and zone I and zone II of RAD51 
 
As previously explained, BRCA2 binds the RAD51 monomers through 8 conserved motifs 
called BRC repeats. Out of these eight motifs, BRC4 is the one with the highest affinity for 
RAD51 and thus we focused our attention on its structure and its interactions with RAD51. 
BRC4 binds RAD51 in two different hydrophobic pockets called zone I and zone II, 
respectively. Zone I pocket can lodge BRC4’s FxxA motif (residues 1524−1527 of BRCA2) 
and binds directly to the oligomerization interface occupying two hydrophobic pockets. 
Those same pockets, in a RAD51 oligomer, are occupied by the RAD51’s FTTA motif that 
mediates inter-subunit contact.  
The zone II pocket can lodge the BRC4’s LFDE motif (residues 1545−1548 of BRCA2), is 
situated far from the oligomerization interface and it is more evolutionarily conserved: 
mutations in this site causes cellular lethality and failure of RAD51 assembly in nuclear foci 
at the site of DNA breaks in vivo [59]. 
The BRC motif is characterized by hydrophobic residues that keep it in close contact with 
RAD51 throughout its length. Three main points of contact stand out, involving residues Phe 
1524, Ala 1527, Leu 1545 and Phe 1546.  
The first two mentioned residues interact with zone I: Phe 1524 is located on the strand of the 
β-hairpin contacting RAD51, and its aromatic ring is buried within a hydrophobic cavity 
formed by RAD51 residues. Ala 1527, in the second position of the hairpin loop, places its β-
carbon into a small pocket formed by the side chains of other RAD51 residues. 
The remaining residues are involved in the zone II interactions: Leu 1545 and Phe 1546 form 
a wedge embedded between RAD51 helices A4 and A5, and surrounded by residues Leu 
204, Tyr 205, Ser 208 (in helix A4), and Met 251, Arg 254, Leu 255, Glu 258 and Phe259 (in 
helix A5) [60] [Figure 2.7]. 
For our project, in order to find an optimal RAD51-BRCA2 disrupting molecule, we focused 
on the synthesis of molecules that could bind these two zones and interfere with the protein-
protein interaction. 
 
During our researches, we managed to synthesize two types of compounds: 
-Zone I inhibitors, who interfered with the interaction between BRCA2 and the zone I of 
RAD51. 








Figure 2.7. (A). Overview of the interactions between BRC4 (Yellow) and Zones I (Red) and II (Blue); RAD51 
is represented as a white surface, BRC4 as a cartoon. (B). Zone II magnification showing the interacting 
residues of BRC4 (yellow) and RAD51 (white). (C). One of our compounds docked into the FxxA domain of 
RAD51. The small molecule recapitulates major interactions the peptide BRC4 establishes with the biological 
target. 
 
2.5 PROJECT B: INHIBITION OF HOMOLOGOUS RECOMBINATION ACTIVITY 
THROUGH THE USE OF LDH INHIBITORS. 
 
2.5.1 Cancer: a metabolic disease 
 
Many studies highlight that cancer can be considered a metabolic disease, characterized by 
aberrant and/or dysregulated glucose metabolism and bioenergetics. Neoplastic cells 
typically show highly increased rates of glucose uptake and glycolysis, after which the 
obtained pyruvate is converted to lactate by lactate dehydrogenase (LDH). [61] 
In normal cells, under aerobic conditions, pyruvate is generated from glucose via glycolysis 
in the cytosol and is used to fuel oxidative phosphorylation, theoretically generating 36 net 
adenosine triphosphate (ATP) per molecule of glucose. Under anaerobic conditions, 
glycolysis is favored and relatively little pyruvate is dispatched to the oxygen-consuming 
mitochondria [62]. 
In cancer metabolism, one of the most well-known phenomena is the Warburg effect. In 
1924, Otto Warburg observed that cancer cells consume much larger quantities of glucose 




levels of lactate even in oxygen-rich conditions, hence the term aerobic glycolysis [Figure 
2.8] [63].  
There are many reasons that explain why cancer cells tend to prefer aerobic glycolysis 
towards oxidative phosphorylation: 
1- Aerobic glycolysis benefits cancer cells by avoiding generation of oxidative stress from 
the electron transport chain: this proves to be extremely useful in a condition when cells 
are constantly replicating [64]. 
2- The aerobic glycolysis provides the intermediates of the citric acid cycle for anabolic 
reactions to synthesize other organic molecules needed by the cell: glucose-6-phosphate 
can be oxidized and used to synthesize nucleotides for DNA and RNA. 
Dihydroxyacetone phosphate is the precursor for the biosynthesis of the fatty acids. 3-
phosphoglycerate provides the carbons for cysteine, glycine and serine, whereas pyruvate 
provides the carbons for alanine [65]. 
3- The overexpression of glycolytic enzymes leads to accumulation of lactate, which causes 
acidification of the tumoral environment. Acidic extracellular pH is a major feature of 
tumor tissue and increases the expression of some genes (VEGF, IL-8) involved with pro-
metastatic factors and can activate enzymes like metalloproteinase and cathepsins that 
disrupt the extracellular matrix [66].  
4- Additionally, lactate itself functions as an intrinsic inflammatory mediator that increases 
interleukin (IL)-17A production by T-cells and macrophages; this results in the 
promotion of chronic inflammation in tumor microenvironments [67]. 
5- Cancer cells evade apoptosis under hypoxic conditions and acquired resistance to 
therapeutic agents. Among various mechanisms that contribute to the evasion of 
apoptosis in cancer, metabolism is emerging as one of the key factors. Cellular 
metabolites can regulate functions of pro- and anti-apoptotic proteins. In turn, p53, a 
regulator of apoptosis, also controls metabolism by limiting glycolysis and facilitating 
mitochondrial respiration. Consequently, with dysregulated metabolism and p53 
inactivation, cancer cells are well equipped to disable the apoptotic machinery [68]. 
A malfunctioning in the oxidative phosphorylation does not cause the increase of the 
glycolytic pathway; in fact, the coexistence of increased glycolysis and oxidative 
phosphorylation is observed in some cancer cells, and these metabolic phenotypes can be 
induced to mutually switch in response to drug or micro-environmental stimulation [69]. This 
enhancement of glycolysis can be induced by hypoxia or hypoxia-induced factor 1 (HIF-1), 
even in the presence of fully functioning mitochondria, and is present in different 
heterogeneous cancer cells and in cancer-associated fibroblasts (CAFs) that also launch 
metabolic reprogramming to support cancer cell growth and metastatic dissemination. HIF-1 
can increase the transcription of glucose transporters (GLUT1, GLUT3), many glycolytic 
enzymes and LDHA [70]. Normally HIF is induced in hypoxic situations but can be induced 




mTOR activation, NAD+ levels, many TCA cycle metabolites, oncogene gain of function 
and tumor suppressor gene loss of function [72]. 
 
Figure 2.8. Metabolic pathways of normal cells (to the left) and cancer cells (to the right). 
 
2.5.2 Lactate Dehydrogenase  
 
Lactate Dehydrogenase (LDH) is an enzyme belonging to the oxidoreductase family. LDH 
inter-converts pyruvate and lactate using nicotinamide adenine dinucleotide (NAD+), an 
essential cofactor that is required for a wide range of cellular reactions including ATP 
production.  
LDH protein is a tetramer, its subunits are produced by three LDH-encoding genes (LDH-a, 
LDH-b and LDH-c) which produce the LDH-A, LDH-B and LDH-C subunits respectively. 
The three genetic loci show 71–75% sequence identity, indicating wide conservation in 
amino acid composition of the LDH subunits [73]. Isoform LDH-A is particularly interesting 
because it has been linked to an actively glycolytic metabolism since it favors the conversion 
from pyruvate to lactate under anaerobic conditions in normal cells [74]. 
The association of A and B isoforms can produce five isozymes: LDH-1 (A0B4), LDH-2 
(A1B3), LDH-3 (A2B2), LDH-4 (A3B1) and LDH-5 (A4B0); The LDH forms enriched in A 
subunits are predominant in skeletal muscle and liver, while those enriched in B subunits are 
mainly found in heart and brain. Isozyme LDH-5 has been reported to be the primary form 
expressed in cancer cells [75]. The subunit LDH-C can only form a homotetramer and it is a 







Regarding the structure of this enzyme, by looking at the crystal structures of the isoforms 
LDH-1 and LDH-5 we can identify two domains [77]:  
1- NADH binding domain:  this area is formed by residues 20–162 and 248–266 and is 
characterized by a ‘Rossmann’ fold, a region of the peptide where three parallel ß-strands 
enclose two alpha-helices. In this region, NADH binds in a groove of the central ß-sheet 
with the His195; Asp168, Arg171, Ile250 and Thr246 are essential residues to assemble 
the geometry of the catalytic site. 
2- Substrate binding domain: it comprises the residues 163–247 and 267–331. The pyruvate 
binding cavity is located at the interface between the two domains, where residues 99–
110 form the so-called ‘active site loop’. 
Recent experiments also evidenced for this enzyme a possible role beyond the mere 
management of pyruvate/lactate balance in glucose metabolism. In fact, similar to other 
glycolytic enzymes, LDH was found to be a protein “moonlighting” in cell nucleus, where it 
could bind to ssDNA and mRNA and take part in transcriptional complexes regulating gene 
expression [78]. The LDH-A subunit is an essential component of the transcriptional 
complex of the histone 2B gene (H2B): the subunit is associated with glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and the coordinated activity of the two enzymes 
maintain the proper NAD+/NADH ratio necessary for optimal H2B protein expression [79]. 
LDHA with tyrosine phosphorylation has also been reported as localized to the nucleus, 
suggesting that tyrosine phosphorylation may play an essential role in LDHA function in the 
nucleus [80]. 
LDH appears to be one of the most interesting potential targets for designing an anti-
metabolic cancer treatment. This enzyme is constantly overexpressed in cancer cells and, 
because of its position at the end of the glycolytic pathway, it is considered not necessary for 
the viability of normal cells, which mainly catabolize pyruvate via the TCA cycle [81]. 
Genetic studies also revealed that LDH-A knockdown inhibits in vitro and in vivo growth of 
certain cancer cell lines [82]. The most studied LDH inhibitor is Oxamate (OXA), a pyruvate 
analogue that inhibits LDH by substrate competition. Researchers demonstrated that 
downregulation of LDH-A by using both LDH-a-targeted siRNA and OXA increased 
tumoral cell death by apoptosis [83]. However, Oxamate is not suitable for in vivo therapies. 
In fact, it has limited cell penetration and therefore relatively high doses are required to have 
any significant effect. It is still highly use in in-vitro studies since it is highly specific and its 
mechanism of action is well known. 
Recently, a promising LDH inhibitor potentially active in vivo has been synthetized: during 
the tests, the suppression of the glycolytic flux through inhibition of the conversion of 
pyruvate to lactate was observed in both in vitro and in vivo models, concomitant with 




effect that could potentially narrow the therapeutic window of this novel compound was 
found to be hemolysis, presumably linked to the metabolic inhibition of red blood cells [84]. 
 
2.5.3 Correlations between LDH activity and DNA repair mechanisms 
 
As previously mentioned, the enhanced glycolysis activity promotes various cancer-essential 
functions other than just providing the cells with higher levels of ATP. One of these 
functions in particular is highly relevant for the purpose of this project: the maintenance of 
tumoral DNA integrity. This is a crucial function for supporting active proliferation, even for 
cancer cells already bearing genetic mutations. Studies mention that when glycolysis activity 
is increased, cancer cells become more proficient in repairing DNA damage and more 
resistant to ionizing radiation [85]. Likewise, considerable amounts of evidences suggest that 
inhibition of glycolysis leads to compromised DNA repair [86].  
Despite all this evidence, the mechanisms linking the glycolysis-based metabolic program to 
DNA repair mechanisms have not been fully understood. A possible explanation could reside 
in the depletion of ATP, since without energy cells would not be able to repair its genome. 
Moreover, an involvement by LDH’s moonlight activities (mentioned in the previous 
chapter) or by its product, the lactate, must be considered. 
Lactate is highly produced in tumoral environment and is one of the factors that promote cell 
invasion via acidification of the extracellular matrix. Moreover, lactate can also affect gene 
transcription by influencing the activity of histone proteins.  
Histone modification by acetylation is an important process in transcriptional regulation. The 
chromatin of transcriptionally active genes is epsilon-amino (ε-NH 2) acetylated on the N-
terminal tails of histone H3 and histone H4, whereas that of inactive genes is hypoacetylated. 
Histone modification and gene regulation arise from the differential recruitment of histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes to chromatin. Lactate can 
inhibit the activity of HDAC proteins and indirectly regulate gene expression; it is important 
to note that expression changes induced by lactate correlate with changes induced by other 
HDAC inhibitors across the entire genome [87]. 
Furthermore, lactate can induce even lactylation of histone’s lysine residues: this lactylation 
process serves as an epigenetic modification that directly stimulates gene transcription from 
chromatin and is remarkably dependent by cellular glycolysis activity [88]. 
Even though the molecular mechanisms that link the glycolytic pathway and the DDR 
pathways are not fully clarified, it is possible that inhibition of LDH could be a valuable 








3. SPECIFIC AIMS 
 
In the past two decades, research has focused on discovering tumor-specific signaling and 
metabolic pathways that might be exploited for pathway-targeted anticancer therapies. 
Currently, several small molecules and monoclonal antibodies have been approved, which 
directly inhibit genes and proteins that are critical in oncogenic signal networks. These have 
increased survival in patients with previously intractable cancers. However, the first 
generation of targeted therapies have some limitations, including the development of 
resistance and on- and off-target toxicities. For these reasons, researchers are increasingly 
turning to precision medicine, using genetic changes in a patient's tumor to determine their 
treatment. Synthetic lethality is a new concept with great potential for discovering new 
anticancer molecules within the framework of precision medicine. 
Synthetic lethality arises when a combination of mutations in two or more separate genes 
leads to cell death, while the single mutated genes do not affect the viability of the cell. 
Using this concept, new anti-cancer strategies that target specific gene defects can be 
implemented, such as the use of OLA in BRCA-less cancer cells. The advantage of those 
therapies is that only cancer cells suffer an increase in cell death while normal cells are 
spared. Unfortunately, their use is limited only in tumors whose cells carry the desired 
mutation.  
In this thesis, we present a new working hypothesis dubbed “fully small-molecule induced 
synthetic lethality”. With this hypothesis, we want to prove that it is possible to strengthen 
the effect of OLA in BRCA-proficient tumors using compounds that can interfere with the 
HR mechanism. 
 
In order to achieve HR inhibition, we used two different approaches. 
In the direct approach (Project A), we used RAD51-BRCA2 disruptors. This protein-protein 
interaction is a focal point in the repair of DNA double strand damage; therefore, disruptors 
should be able to mimic a BRCA-less cellular environment. We focused our research on 
compounds that could bind to Zone I and II of RAD51, the two hydrophobic pockets that 
interact with BRCA2. 
The efficacy of new synthetized RAD51-BRCA2 disruptors was tested by comparing their 
effects on cell lines with different DNA repair efficiency:  
 BxPC3: a BRCA2 competent cell line  
 Capan-1: a cell line expressing a non-functional BRCA2 protein  
 
In the indirect approach (Project B), we inhibited HR by interfering with the cellular 
metabolism through inhibition of LDH activity. Various studies suggest a possible 
connection between the activity of this enzyme and the efficiency of DNA repair pathways. 
In order to evaluate the effect of LDH inhibition on HR, we decided to use cells 




 BxPC3: a cell line that relies mostly on LDH activity and glycolysis for its energy 
metabolism 
 SW620: a cell line showing an energy metabolism more dependent on oxidative reactions 
 
Both Project A and project B have the same objectives: 
1. To characterize the in vitro effects of the tested compounds on the HR mechanism 
2. To determine if their activity on the HR mechanism could effectively mimic a BRCA-less 
environment and induce synthetic lethality by administering them alongside OLA. 
It is important to note that, in the original PARPi therapies, only cells bearing BRCA 
mutations were affected by OLA, while our new approach would target both normal and 
cancer cells. However, cancer cells rely on DDR pathway and LDH activity more often than 


























4. MATERIALS AND METHODS 
 
4.1 Cell Culture 
 
For the experiments we used two different pancreatic adenocarcinoma cell lines, BxPC3 and 
Capan-1, a human colon adenocarcinoma cell line called SW620 and a normal immortalized 
cell line called HK-2. The cell lines were obtained from ATCC. 
BxPC3 cell line was derived from a 61-year-old woman and expresses a functional BRCA2 
protein. Capan-1 cell line harbors a single base-pair deletion in the BRCA2 allele, which 
results in the expression of a truncated and dysfunctional protein. 
Both pancreatic cell lines were grown in RPMI 1640 containing 10% FBS, 100 U/ml 
penicillin/streptomycin and 2 mM glutamine. The media and the other supplements were 
obtained from Sigma-Aldrich. 
Non-neoplastic, immortalized cells from human kidney, HK-2, were grown in DMEM/F-12 
containing 40 ng/mL dexamethasone, while SW620 cells were grown simply in DMEM; 
both of these media have been supplemented with 10% FBS, 100 U/ml 
penicillin/streptomycin and 2 mM glutamine. 
In the experiments that involved OLA, media were supplemented with 0.6% DMSO; the 
same amount of DMSO was added to the untreated cultures as well.  
 
4.2 Viability Assays 
 
4.2.1 CellTiter-Glo ATP Assay 
 
CellTiter-Glo Luminescent Cell is a Viability Assay developed by Promega. For this 
experiment, 1 x 104 cells in 200 μl of culture medium were seeded into each well of a 96-
multiwell white body plate and allowed to adhere overnight. The following day the cells 
were treated with the desired compounds, administered alone or in combination. After the 
incubation, whose time differed based on the various experiments, the plate was allowed to 
equilibrate for 30 min at room temperature and then 100 μl CellTiter-Glo reactive were 
directly added to each well. The plate was kept on a shaker for 2 min followed by 10 min of 
incubation at room temperature, to induce cell lysis. Luminescence was measured by using a 
Fluoroskan Ascent FL reader (Labsystems). 
 
4.2.2 Neutral Red Assay 
 
Cells (1-2 x 104/well) were seeded in two 96-well plates. At the end of the treatment, cells 
were maintained in medium containing 30 μg/ml Neutral Red for 3 h. Medium was then 
removed and the cells were solubilized with 200 µl of 1% acetic acid in 50% ethanol. The 




EX, ThermoLab Systems). To estimate cell numbers, before each experiment a plot reporting 
the Neutral Red absorbance values obtained from scalar amounts of cells was acquired.  
 
4.3 Lethality assays  
 
4.3.1 CellToxTM Green Cytotoxicity Assay 
 
Cells (1 x 104/well) were plated in 96-well plates and treated with the desired compounds, 
given alone or in combination. At the end of treatment, the CellToxTM dye was added to cell 
cultures and the green fluorescence signal, which is produced by the binding interaction with 
dead cell DNA, was measured using an EnSpire 2300 multilabel reader (Perkin Elmer) with a 
512nm excitation wavelength and a 532nm emission wavelength. As a positive control, cells 
were treated with lysis buffer 1:50 (Promega). 
 
4.3.2 Vital dyes assay 
 
Cells were grown on coverslips placed in a 6-multiwell plate (5 x 105 cells/well). After a 
48h/72h treatment with the desired compounds, given alone or in combination, wells were 
rapidly washed with PBS and filled with 500 µl of PBS solution containing 4′,6-diamidino-2-
phenylindole (DAPI, 4.6 μg/ml) and propidium iodide (PI, 50 μg/ml). After a 10 min 
incubation at room temperature under light-shielded condition, BxPC3 cells were washed 
with PBS, fixed (10 min) with 10% neutral buffered formalin solution and washed again to 
eliminate excess fixative. Coverslips were then applied on glass slides using two drops of 
mounting media: 200 μg/ml 1,4-diazabicyclo[2.2.2]octane (DABCO) 20 mM Tris-HCl, 90% 
glycerol. Images were acquired on a Nikon fluorescent microscope equipped with filters for 
DAPI and PI. 
 
4.4 Homologous recombination Assay 
 
Homologous recombination (HR) efficiency was assessed by using a commercially available 
assay (Norgen). This assay is based on cell transfection with two plasmids that, upon cell 
entry, can recombinate. The HR product can be assessed by both PCR and real time PCR, 
using primer mixtures included in the assay kit. Different primer mixtures allow to 
discriminate between the original plasmid backbones and their recombination product.  
BxPC3 and SW620 cells (2 × 105 per well) were seeded in a 24-well plate and allowed to 
adhere overnight. Co-transfection with the two plasmids was performed in Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s instructions and left for 5h. Cells were 
exposed to different doses of treatments, dissolved in RPMI in the presence of 0.6% DMSO 




and DNA was isolated using IllustraTM Tissue and Cell Genomic Prep Mini Spin kit (GE 
Healthcare). Sample concentration was measured using an ONDA Nano Genius photometer.  
In the first experiments, the efficiency of HR was assessed by standard PCR performed 
according to the manufacturer's instructions and using 100-150 ng of template. The 
amplicons of plasmid backbones and of recombination product were separated by 
electrophoresis on 2% agarose gel. Band intensity was measured by Kodak Electrophoresis 
Documentation and Analysis System (EDAS) 290 and used to evaluate HR efficiency, which 
is given by the ratio: [Recombination Product/Backbone Plasmids]. 
In further experiments, to improve data quantification, the same assay was performed using 
real-time PCR. 
Real-time PCR was performed by using 25 ng of template, the primer mixtures included in 
the assay kit and following the protocol indicated by the manufacturer. Data analysis was 
based on the ΔΔCt method: [Recombination Product / Backbone Plasmids] treated versus 
[Recombination Product / Backbone Plasmids] control. 
 
4.5 Western Blot analysis 
 
Cell cultures (1.5 x 106 cells) were exposed to the desired compounds, given alone or in 
combination. After the incubation, cells were lysed in 60-100 µL RIPA buffer containing 
protease and phosphatase inhibitors (Sigma Aldrich). The homogenates were left 30 min on 
ice and then centrifuged 15 min at 10000 g. From 30 µg to 50 µg proteins of the supernatants 
(measured according to Bradford) were loaded into 4-12% polyacrylamide gel for 
electrophoresis and run at 170V. The separated proteins were blotted on a low fluorescent 
PVDF membrane (GE Life Science) using a standard apparatus for wet transfer with an 
electrical field of 80 mA for 16 h. The blotted membrane was blocked with either 5% BSA in 
TBS-Tween, or 2.5% BSA and 2.5% Casein in TBS-Tween depending on the antibody, and 
probed with the primary antibody. The antibodies used were: rabbit anti-γH2AX [phosphor 
S139] (Abcam), mouse anti BCL-2 (Santa Cruz), rabbit anti BAX (Abcam), rabbit anti-Actin 
(Sigma Aldrich). Binding was revealed by a Cy5-labelled secondary antibody (anti rabbit-
IgG, GE Life Science; anti mouse-IgG, Jackson Immuno-Research). All incubation steps 
were performed according to the manufacturer's instructions. Fluorescence of the blots was 
assayed with the Pharos FX scanner (BioRad) at a resolution of 100 µm, using the Quantity 
One software (BioRad). 
 
4.6 Micronuclei visualization  
 
For micronuclei visualization, BxPC3 cells were grown on coverslips placed in a 6-multiwell 
plate (5 x 105 cells/well). After a 72 h treatment with olaparib and/or RAD51-BRCA2 
disruptors, cells were rapidly washed with PBS and then fixed for 10 min with cold 




DABCO solution (described in 3.3.2 paragraph). Images were acquired on a Nikon 
fluorescent microscope equipped with filters for DAPI.  
A cell was considered to contain micronuclei if the following criteria were met: (i) one or 
more round fluorescent bodies were present in the cytoplasm, which did not touch the main 
nucleus; (ii) they were < 1/3 of the main nucleus diameter; and (iii) they were nonrefractile, 
to exclude foreign bodies. Two independent observers estimated the percentage of cells 
bearing micronuclei, by analyzing 100-250 cells for each treatment sample. 
 
4.7 Immunofluorescence experiments 
 
Immunofluorescence was used for studying RAD51 nuclear translocation and for evaluating 
DNA damage through the detection of γH2AX nuclear foci.  
To visualize RAD51 in cell nuclei, the cells were seeded on glass coverslips placed in a 6-
well culture plate (2 × 105 cells/well) and allowed to adhere overnight. Cultures were then 
preincubated with ARN 24089 (1h incubation) or OXA (16h incubation) and subsequently 
exposed to 50 μM cisplatin for an additional 1.5 h. Medium was removed, and cells were 
maintained in the presence of ARN 24089 or OXA for 4h/5h. After this time, cultures 
growing on coverslips were fixed in PBS containing 1% formalin for 20 min, permeabilized 
in 70% ethanol, air-dried, and washed twice with PBS. Samples were incubated in 10% 
bovine serum albumin (BSA) in PBS for 30 min at 37 °C and subsequently exposed to an 
anti-RAD51 mouse monoclonal antibody (Santa Cruz Biotechnology, 1:1000 in 5% 
BSA/PBS) overnight at 4 °C. After washing, coverslips were incubated with an anti-mouse 
FITC-conjugated secondary antibody (1:1000 in 1% BSA/PBS) for 1 h at 37 °C, washed, air-
dried, and mounted with a solution of DAPI (2 μg/mL) and DABCO solution (described in 
3.3.2 paragraph). 
To evaluate DNA damage through γH2AX nuclear foci, BXPC3 and Capan1 cells were 
seeded on glass coverslips in 6-well tissue culture plate (2 × 105 cells/well) and allowed to 
adhere overnight. After 48 h treatment with OLA (10 μM) or ARN 24089 (20 μM) given 
alone or in combination, cultures growing on coverslips were fixed and treated as described 
above. For this experiment, the used antibodies were a rabbit polyclonal anti-γH2AX 
(Abcam, 1:1000 in 
5% BSA/PBS) and a secondary anti-rabbit rhodamine-labeled (Novus Biologicals, 1:1000 in 
1% BSA/PBS). For both experiments, images were acquired using a Nikon fluorescent 
microscope equipped with filters for FITC, TRITC, and DAPI. The percentage of cells 
bearing 
nuclear foci was estimated by two independent observers, by analyzing 100−250 cells for 







4.8 Real-Time PCR 
 
Cells were seeded in T25 flasks (7 x 105 cells / flask) and allowed to adhere overnight. 
Cultures were then exposed to oxamate for additional 16 h: a 40 mM dose was used for 
SW620 cells; 20 mM for BxPC-3 cells. RNA was extracted using the PureZOL isolation 
reagent (Bio-Rad) and was quantified spectrophotometrically. Retro-transcription to cDNA 
was performed by using the Revert Aid™ First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific), in different steps: 5 min denaturation at 65°C, 5 min annealing at 25°C, 1 h retro-
transcription at 42°C and 5 min inactivation at 70°C. Real Time PCR analysis of cDNA (15 
ng) was performed using SYBR Green Supermix (SSO Advanced, BioRad). The sequence of 
primers used for analyzing expression of the studied proteins and of the internal control 
genes are reported in Table 4.1. 
For all examined genes, annealing temperature of primers was 60°C and the thermal cycler 
(CFX96 TM Real Time System, BioRad) was programmed as follows: 30 sec at 95°C; 40 
cycles of 15 sec at 95°C; 30 sec at 60°C. 
 
Table 4.1. List of primer sequences used for RT-PCR analysis. 
Gene Forward primer (5’ – 3’)  Reverse primer (5’ – 3’)  
LDH-A GACCTACGTGGCTTGGAAGA  TCCATACAGGCACACTGGAA  
LDH-B CCAACCCAGTGGACATTCTT  AAACACCTGCCACATTCACA  
BRCA1 TATCCGCTGCTTTGTCCTCA  TGCAGGAAACCAGTCTCAGT  
BRCA2 GAGAGTTCCCAGGCCAGTAC  ACTGGAAAGGTTAAGCGTCA  
NBN (Nibrin or P95) CCACCTCCAAAGACAACTGC  TCAGGACGGCAGGAAAGAAA  
MRE11  
(Double Strand Break 
Repair Nuclease) 
TGTTGAGGTTGCCATCTTGA  TGATCAGTCAGTCAACTTTGGT  
RAD50  
(Double Strand Break 
Repair Protein) 
CTGCTTGTTGAACAGGGTCG  CCAATTCTAGCTGTGTTGCCA  
RAD51 (Recombinase) CAAATGCAGATACTTCAGTGGAA  TCCAGCTTCTTCCAATTTCTTCA  
DCLRE1C  
(DNA cross-link repair 1C 
or Artemis) 
TTCTCCCTATCGAAGCGGTC  ATGAGTTCTTTCGAGGGGCA  
LIG4 (DNA Ligase 4) GGTCGTTTACTTGCTGTATGGT  TGCATATTTTGTGTTGAAGCCA  
PRKDC (DNA-PK) GAGCTCAACGTACATGAAGTCA  TGTGGATTCGAACAACAAGGAG  
XRCC4 (X-ray repair cross 
complementing 4) 
GCATTGTTGTCAGGAGCAGG  TGAAGGAACCAAGTCTGAATGAG  
XRCC5 (X-ray repair cross 
complementing 5 or Ku80) 
AGAATCCCCATTTGAACAAGCA  GAAAGGGGATTGTCAGTGCC  
XRCC6 (X-ray repair cross 
complementing 6 or Ku70) 
GGGCAAGATGAAGGCTATCG  GTTCCGGCTCCATCAAATCC  
LIG1(DNA Ligase 1) CACCACTCCATTCCACTCCT  AGGGAGAATTCTGACGCCAA  
PARP1 (Poly(ADP-ribose) 
polymerase 1) 





(Werner syndrome RecQ 
like helicase) 
AGTTCTTGTCACGTCCTCTGG  GGTGCCTATTTAAGTTAATGTCTGC  
XRCC1  
(X-ray repair cross 
complementing 1) 
TCCCAATGTCCACACTGTGT  TCAAGGCAGACACTTACCGA  
CYP33A 
(Cyclophilin 33A) 
GCTGCCTGTGCACTCATGAA  CAGTGCCATTGTGGTTTGTGA  
GUSB 
(Glucuronidase Beta) 
CTCATTTGGAATTTTGCCGATT  CCGAGTGAAGATCCCCTTTTTA  
RPS13 
(Ribosomal Protein S13) 
CCCCACTTGGTTGAAGTTGA  ACACCATGTGAATCTCTCAGGA  
TUBA 
(Tubulin Alpha) 
TGGAACCCACAGTCATTGATGA  TGATCTCCTTGCCAATGGTGTA  
 
4.9 Measurement of lactate levels 
 
For this assay, 5 x 105 cells were seeded in 6-well plates and opportunely treated the day after 
in triplicate. At the end of the treatment, the medium was replaced with 1 ml of Krebs-Ringer 
buffer (118 mM NaCl, 4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM KH2PO4, 1,2 mM 
MgSO4•7H2O, 24.6 mM NaHCO3, glucose 4 mg/ml) and scalar concentrations of OXA. 
Lactate levels were measured in two untreated wells at the start of experiment (baseline 
value) and 3h (or 6h) after incubation at 37°C. 
At the end of incubation 100 l of 100% trichloroacetic acid (TCA) was added to each well. 
Therefore, the cells were collected, lysated and centrifuged at 1700g for 5 minutes. At the 
end of the centrifugation, the lactate in the supernatant was measured according to the 
method of Barker and Summerson [91]. The amount of metabolite formed during the 3h 
incubation with or without the LDH inhibitor was calculated from a standard curve and 
subtracting the baseline value. The lactate concentration in the various samples and in the 
standard curve was read with a spectrophotometer at λ=565nm.  
 
4.10 Statistical analysis 
 
All data were analyzed by using the Prism 5 GraphPad software. Each experiment was 
performed with triplicate samples per treatment group. Results are expressed as mean ± SE 











4.11 Combination Index 
 
The interaction index between OLA and RAD51-BRCA2 disruptors/OXA was assessed by 
applying the following formula:  
(Surviving cells treated with combination) / [(Surviving cells treated with OLA) X 
(Surviving cells treated with Rad51-BRCA2 disruptor/OXA)] 
As described in the paper [89], a result ranging from 0.8 to 1.2 denotes an additive effect. 















































































5. RESULTS AND DISCUSSION 
 
5.1 PROJECT A: INHIBITION OF HR THROUGH THE USE OF RAD51-BRCA2 
      DISRUPTORS 
 
5.1.1 ZONE I RAD51-BRCA2 DISRUPTORS 
 
Targeting protein-protein interactions (PPI) is an attractive strategy for designing innovative 
drugs. However, it is rather difficult to identify and optimize PPI disruptors. This is because 
proteins usually interact with other proteins via shallow surface sites. In a previous work, 
researchers from Italian Institute of Technology and from FaBiT department of the University of 
Bologna identified a potentially suitable pocket, often referred to as the “FxxA pocket”( zone I). 
This zone is one of the two RAD51 regions where BRC4 (i.e. the fourth BRC repeat responsible 
for binding of BRCA2 to RAD51) binds its counterpart. After a virtual screening campaign 
based on high-throughput docking at the FxxA pocket a series of triazole-based compounds were 
identified. Subsequent ELISA biochemical assay and biological assay showed that two of them 
were able to disrupt the RAD51-BRCA2 interaction and therefore were selected as initial hit 
compounds. 
Notably, triazoles bear a peculiar structure that makes them particularly suited to disrupting 
protein-protein interactions.  In fact, the binding mode to RAD51, as obtained by docking 
simulations, shows noticeable similarities to the crystallographic structure of RAD51 in complex 
with BRC4. To improve the protein-protein inhibitory activity of those two molecules, a 
chemical modification campaign was conducted around the triazole moiety and new analogues 
were synthesized. To investigate their mechanism of action, the ability of compounds to inhibit 
RAD51-BRCA2 interaction was investigated with a competitive biochemical ELISA assay in 
comparison initial hit compounds. This assay is effective in evaluating the ability of new 
molecules to compete with BRC4 to bind to RAD51.  
 
5.1.1.1 Preliminary selection of Zone I disruptors 
The most promising compounds at the ELISA assay (ARN 21560, ARN 21627, ARN 21689 and 
ARN 21730) were submitted to cell-based studies. ARN 21689 and ARN 21730 were discarded 
because of poor solubility. The remaining two compounds were characterized in human 
pancreatic carcinoma, using BxPC3 cells [Table 5.1]. These cells were chosen for their clinical 
relevance and for the possibility of using Capan-1 cells, which lack functional BRCA2 protein 
and could therefore serve as negative control. Additionally, BxPC3 and Capan-1 match well in 
terms of tumor type and differentiation state. 
Table 5.1. . List of tested compounds and respective IC50 
Compounds IC50 Elisa IC50 Viability 
ARN 21560 10 µM 37 µM 
ARN 21627 29 µM >50 µM 
ARN 21689 42 µM N.S.a 
ARN 21730 33 µM N.S.a 






The RAD51-BRCA2 interaction is crucial in recruiting the recombinase RAD51 to cell nuclei, 
where it uses homologous recombination (HR) to repair double-strand breaks. We therefore 
studied HR inhibition in BxPC3 and Capan-1 cells. The assay is based on cell transfection with 
two plasmids bearing the LacZ sequence, each with a different mutation. In transfected cells, the 
recombination machinery restores the corrected LacZ sequence, which can be detected by PCR. 
Using two different primer sets, both the plasmid couple and the recombination product can be 
measured, allowing an estimation of HR efficiency.  
Both compounds reduced HR in treated BxPC3 cells suggesting their potential ability to disrupt 
RAD51-BRCA2 interaction in living cells too. Of the two molecules, ARN 21560 had the 
strongest effect, with a statistically significant 40% inhibition at 20 mM. ARN 21627 showed a 
less marked effect, with a 24% inhibition at 40 mM. The limited solubility of ARN 21627 further 
hindered a dose escalation with this compound. [Figure 5.1].  
 
Figure 5.1. Estimation of homologous recombination efficiency in BxPC-3 cells treated (16 h) with the newly 
identified BRCA2-RAD51 disruptors ARN 21560 (A) and ARN 21627 (B). *, p < 0.05 as evaluated by ANOVA 




The HR data suggested that ARN 21560 and ARN 21627 were potentially capable of synergizing 
with OLA in pancreatic cancer cells with functional BRCA2, where OLA usually is inactive. The 
two compounds were therefore tested in BxPC3 and Capan-1 cell viability experiments in 
combination with OLA. 
After 72 h of treatment, ARN 21627 did not affect the efficacy of OLA [Figure 5.2, B]. 
Conversely, ARN 21560 significantly increased OLA’s efficacy in BxPC3 cells, without 
affecting its efficacy in the BRCA2-defective cells (Capan-1) [Figure 5.2, A].  
These results further confirmed, in a dose-dependent manner, that HR inhibition might explain 
the synergistic effect of combining RAD51-BRCA2 disruptors with PARP inhibitors in cell lines 
with fully functional BRCA2, where PARP inhibitors are usually inactive. Further experiments 
were conducted on ARN 21560 to confirm the synergy with OLA.  
 
 
Figure 5.2. Evaluation of cell viability assessed in combination experiments with OLA (10 mM) + ARN 21560 (A) 
or ARN 21627 (B) on BxPC-3 and Capan-1 cultures. The doses showing the best results in the experiments were 





5.1.1.2 Western Blot analysis on γ-H2AX bands 
 
Using the same exposure time we used in the previous experiments, an immunoblotting 
evaluation of DNA damage was also performed by measuring the phosphorylation of H2AX (γ-
H2AX), a sensitive and universal indicator of DNA double-strand break formation.  
The densitometric evaluation of γ-H2AX bands, normalized on actin levels, have been plotted in 
the bar graph. It shows that, in cells treated with the combination of OLA with ARN 21560, the 
DNA damage signal was >70% higher than the one observed in control and in OLA-treated cells. 
This experiment also showed that, when given as a single treatment, ARN 21560 did not cause 
appreciable signs of DNA damage. [Figure 5.3]. 
 
Figure 5.3. (A). Western blot showing Actin bands and γ-H2AX bands: samples were isolated from BxPC3 cells 
treated for 144h with 10 µM OLA and 20 µM ARN 21560. (B). graph showing the intensity of the γ-H2AX bands, 
normalized on Actin levels. 
 
5.1.1.3 Lethality Assay on BxPC-3 and Capan-1 cells 
 
Further experiments were conducted on ARN 21560 to confirm the synergy with OLA. 
By adopting a longer exposure time to treatments (144 h), we assessed how the ARN 
21560+OLA combination affected cell viability and cell death. Cell death was evaluated using 
the CellTox Green Dye (Promega) probe, which emits a fluorescence signal only in the presence 
of cells with impaired membrane integrity. Again, we observed a statistically significant increase 
in OLA's power in reducing cell viability. The data of the cell viability experiment were also 
used to evaluate the combination index (CI) between OLA and ARN 21560. According to this 
method, CI < 0.8 indicates synergism while a result ranging from 0.8 to 1.2 indicates additive 
effects. A CI value of 0.76 ± 0.03 was obtained, which suggests yet again a potential synergistic 
effect between the compounds. 
However, when we analyzed the data obtained from the lethality assay, the enhanced OLA 
potency did not produce evidence of increased cell death. Despite the results obtained in the 
previous experiments, we could not fully reproduce the paradigm of synthetic lethality with ARN 





Figure 5.4. (A). Viability data showed for comparison: BxPC3 and Capan-1 cells treated for 144h with 20 µM ARN 
21560 and 10 µM olaparib (*: p < 0.05 evaluated by ANOVA followed by Dunnet's post-test). (B). Cell death data: 
BxPC3 and Capan-1 cells treated for 144h with 20 µM ARN 21560 and 10 M olaparib. 
 
5.1.1.4 Project A final discussion (Zone I disruptors) 
 
In recent years, innovative anticancer treatments have relied on targeted therapies to improve 
drug efficacy and reduce side effects. In parallel, precision medicine has provided a new 
paradigm for identifying individual patients or groups of patients for treatment with tailored 
pharmacological medications. For example, PARP inhibitors were recently been approved to 
treat ovarian cancer in patients with genetic mutations in the BRCA genes (1 and 2). 
This has been demonstrated in ovarian cancer (for which OLA was originally approved), and in 
clinical trials in breast and pancreatic cancers. Pancreatic cancer is a major unmet medical need. 
Our work is based on a new paradigm dubbed “fully small-molecule induced synthetic lethality.” 
This paradigm was based on the assumption that, by using a small organic molecule to disrupt 
the RAD51-BRCA2 interaction, it is possible to mimic the effect of BRCA2 germline mutations, 
thus widening the population of patients eligible for treatment with OLA and other PARPi. 
In the first part of this study, we improved the biological screening cascade with experiments 
designed to confirm the molecular mechanism of action (disruption of RAD51-BRCA2 




relative to the initial hits (according to a biochemical ELISA essay) and a clear mechanism of 
action, allowing synergy with OLA in pancreatic cancer cells (BxPC3) where OLA is normally 
inactive. 
Given our initial results, we could conclude that ARN 21560: 
1- inhibited the RAD51-BRCA2 interaction, 
2- hit its target and inhibited its function in living cells, 
3- significantly increased the therapeutic power of OLA alone in cells with a functional 
RAD51-BRCA2 pathway, where usually OLA is inactive, 
4- increased the formation of double-strand breaks when administered in combination with 
OLA. 
Unfortunately, the lethality experiments showed that OLA-ARN 21560 association did not 
trigger synthetic lethality. This could have been due to the low-level potency of our disruptor, 
which did not cause HR inhibition greater than 40%. In addition, the inherent resistance to 
apoptosis of BxPC3 cells, which bear a mutant p53, could have further prevented the synthetic 
































5.1.2 ZONE II RAD51-BRCA2 DISRUPTORS 
 
In a second step of our work, with the intention of identifying novel RAD51-BRCA2 disruptors, 
researchers from Italian Institute of Technology and FaBit department of University of Bologna 
used the available X-ray crystallographic structure of the fourth BRC repeat (BRC4) in complex 
with the catalytic domain of RAD51. They performed a second virtual screening campaign 
targeting the LFDE binding pocket (Zone II). This binding pocket is more evolutionarily 
conserved than the FxxA (Zone I). Furthermore, mutation at the LFDE causes cellular lethality 
and failure of RAD51 assembly in nuclear foci at the site of DNA breaks in vivo. This further 
suggests this pocket has a critical site for RAD51’s mechanism of action. To the best of our 
knowledge, no inhibitor that binds the LFDE binding pocket has been reported so far in the 
literature.  
IIT researchers selected, purchased, and tested 42 small molecules for their inhibitory activity 
using a competitive biochemical ELISA assay. Among the tested compounds, a commercially 
available dihydroquinolone pyrazoline derivative (named 4d [Table 5.2]) was the best candidate 
in terms of EC50 and chemical tractability. The binding mode to RAD51 of both enantiomers of 
4d, as obtained by induced-fit docking simulations, displays some points of interaction similar to 
those of the crystallographic BRC4-RAD51 complex. To improve the RAD51-BRCA2 
inhibitory activity of 4d, researchers conducted a chemical modification campaign around the 
dihydroquinolone pyrazoline core in order to synthetize more efficient Zone II disruptors. This 
new series of dihydroquinolone pyrazoline molecules showed interesting results in the Elisa 
assays, with values ranging from 0.95 to 20 μM. 
 
5.1.2.1 Preliminary selection of Zone II disruptors 
 
To investigate the mechanism of action of the new compounds, different biological assays were 
performed. Our preliminary screening consisted of verifying the efficacy of compounds in 
inhibiting cell HR and/or in increasing the antiproliferative effect of OLA. For each compound, 
both parameters were verified using only one or two doses, in the range of the EC50 obtained 
with the ELISA test. HR activity was assessed by evaluating the recombination rate between two 
transfected plasmids, using a commercially available assay.  
This preliminary investigation allowed us to rapidly exclude molecules showing: 1. low or no 
activity; 2. poor solubility in cell culture media; 3. a non-dose-dependent effect; 4. discrepancy 
between the data obtained in the two different screening procedures (e.g., HR inhibition not 
confirmed by increased OLA efficacy in the viability assay or, on the contrary, increased OLA 
efficacy without HR inhibition). 
The data reported in Table 5.2 show a list of the tested compounds and the results we obtained. 
ARN 24089 (In the table reported as compound 35d) was the most promising one in the HR 









Table 5.2 Preliminary Biological Screening of Compounds Showing EC50 on ELISA Assay Ranging from 0.95 to 20 
μM. ARN 24089 (35d) results are highlighted. 
 
aNE: Not Evaluable, bNDD: Not Dose Dependent 
 
 
Figure 5.5 Effect on HR caused by ARN 24089 administered to BxPC3 cells during plasmid transfection (5 h). The 
observed inhibitory effect was significantly different from 0 (the level of untreated cultures) for all tested doses, with 




To further characterize the effect of ARN 24089 on HR, the compound was administered at 
different doses to BxPC3 cells for 5 h simultaneously with plasmid transfection. ARN 24089 
produced a statistically significant dose−response effect in reducing cell HR. The compound was 
tested up to 40 μM (an upper limit in terms of solubility), and we estimated the dose causing a 
50% inhibition of HR by applying the polynomial regression to the collected data. The EC50 was 
18.4μM [Figure 5.5]. 
 
5.1.2.2 Immunohistochemical staining of RAD51 and γ-H2AX nuclear foci 
 
An additional evidence of compromised HR was obtained by assessing the localization of 
RAD51 in BxPC-3 nuclei after DNA damage. To obtain massive DNA damage, BxPC-3 cultures 
were exposed for 1 h to 50 μM cisplatin (CPL). The immunohistochemical staining of RAD51 
revealed evident nuclear foci in CPL-treated cells, which appeared significantly reduced when 
the drug was administered in association with 20 μM ARN 24089. Furthermore, the percentage 
of RAD51-labeled nuclei measured in cultures exposed to 20 μM ARN 24089 was 
superimposable to that observed in cells exposed to the association of cisplatin with 20 μM ARN 
24089 [Figure 5.6]. 
 
Figure 5.6. Immunofluorescence detection of RAD51 in BxPC-3 nuclei after a treatment with 50 μM cisplatin (CPL) 
given separately or in combination with 20 μM ARN 24089. (A) Representative pictures showing DAPI-stained cell 
nuclei and the corresponding immuno-labeling of RAD51localization. In untreated cells (CTR), RAD51 labeling is 
clearly evident in cytoplasm and does not appear in cell nuclei. In the pictures of CPL-exposed cells, nuclear 
localization of the protein is clearly evident in 3 out of the 6 shown nuclei. (B) The bar graph shows the percentage 
of RAD51-labeled nuclei counted by two independent observers who analyzed the treated cultures. Data were 
statistically evaluated by applying the one-way ANOVA, which indicated a significantly increased nuclear RAD51 
labeling caused by CPL (p <0.05) and no statistically significant difference between cells treated with ARN 24089 
and those exposed to the combination. 
 
The sustained inhibition of HR in cells should result in increased DNA damage, ultimately 
leading to mutations and chromosome aberrations; these effects are expected to be further 
amplified by PARP inhibition. The extent of DNA damage produced in cells treated for 48 h 




by evidencing nuclear γ-H2AX foci by immunofluorescence. The experiment was performed on 
both BxPC-3 and Capan-1 cultures.  
The microscope pictures showed increased evidence of γ-H2AX labeling in nuclei of BxPC-3 
cells exposed to the compounds’ association, compared to the labeling observed in cultures 
treated with OLA. In Capan-1 cultures, the constitutive γ-H2AX labeling in nuclei appeared 
more evident than that observed in BxPC-3 cells. Moreover, in agreement with data showing 
higher PARP inhibitor sensitivity for cells lacking functional HR, these cultures showed 
increased nuclear labeling when exposed to OLA. Notably, this labeling was not further 
enhanced by ARN 24089 co-administration [Figure 5.7]. 
 
Figure 5.7. Evaluation of DNA damage through immuno detection of nuclear γ-H2AX foci in BxPC-3 and Capan-1 
cells exposed for 48 h to OLA (10 μM) or ARN 24089 (20 μM), given alone or in combination. A. DAPI-stained 
BxPC-3 cell nuclei and the corresponding immuno-labeling of γ-H2AX. Co-administration of ARN 24089 and OLA 
produced increased γ-H2AX labeling. B. DAPI-stained Capan-1 cell nuclei and the corresponding immuno-labeling 
of γ-H2AX. As expected, Capan-1 cells showed a constitutive γ-H2AX labeling that was highly increased by OLA but 
was unaffected by ARN 24089 co-administration.  C. The bar graph shows the percentage of γ-H2AX -labeled nuclei 
counted by two independent observers who analyzed the treated cultures. Data obtained in bxPC-3 cells were 
statistically evaluated by applying the one-way ANOVA, which indicated a statistically significant difference 
between the cultures treated with olaparib and those exposed to OLA+ARN 24089 (p<0.05). 
 
5.1.2.3 Micronuclei visualization in BxPC3 treated cells 
 
The sustained and increased DNA damage produced in BxPC-3 nuclei generates chromosomal 
aberrations which can be visualized through the presence of small DNA-staining bodies outside 




BxPC3 cells exposed for 72 h to 20 μM ARN 24089, administered alone or in combination with 
10 μM OLA. Notably, cells bearing micronuclei were markedly more frequent in cultures treated 
with the ARN 24089+OLA combination. Taken together, the results significantly support the 
requested mechanism of action for ARN 24089. Therefore, we conducted further experiments to 
test whether their combination would induce synthetic lethality. [Figure 5.8]. 
 
 
Figure 5.8. Evaluation of micronuclei generation in BxPC3 cells treated (72 h) with ARN 24089 and OLA, given 
alone or in combination. A. Representative pictures showing DAPI-stained cell nuclei. White asterisks indicate the 
presence of micronuclei. B. The percentage of cells bearing micronuclei was estimated by two independent 
observers, by analyzing 100−250 cells for each treatment sample. The obtained results were statistically analyzed 
by applying the one-way ANOVA, which indicated a p value of <0.01. 
 
5.1.2.4 Cell death evaluation in ARN 24089+OLA associations 
 
We simultaneously evaluated cell viability and cell death, measured at 72 h in BxPC3 cells 
exposed to ARN 24089 alone or in combination with 10 μM OLA. The statistical analysis 
compared the results for cultures treated with different doses of ARN 24089 or the ARN 
24089+OLA combination. When applied to the data of the cell viability experiment, this analysis 
indicated a statistically significant difference produced by ARN 24089 in combination with OLA 
in all the treated BxPC3 cultures, with p values ranging from 0.01 (10 μM ARN 24089) to 
0.0001 (15 and 20 μM ARN 24089) [Figure 5.9, A]. When we applied the same analysis to the 
data of the cell death experiment, we found no statistically significant increase in cell death for 
OLA when co-administered with 10−15 μM ARN 24089. Conversely, in cultures exposed to 
OLA + 20 μM ARN 24089 (the concentration that produced the highest HR inhibition in the 
previous experiments) the evidence for cell death was markedly increased and statistically 






Figure 5.9. BxPC3 cell viability (A) and death (B) measured after 72 h exposure to ARN 24089 and 10 μM OLA, 
given alone or in combination. Data were analyzed by two-way ANOVA using the two treatments as variables. In 
the cell viability experiment, Bonferroni post-test indicated a statistically significant difference produced by OLA 
co-administration in all BxPC3 cultures treated with the different ARN 24089 doses, with p values ranging from 
0.01 (10 μM) to 0.0001 (15 and 20 μM). The same analysis was applied to the data from the cell death experiment 
and indicated that no statistically significant increase in cell death was produced by OLA when co-administered 
with 10−15 μM ARN 24089. In cultures exposed to OLA + 20 μM ARN 24089 the evidence for cell death was 
markedly increased and statistically significant, with p < 0.0001. 
 
When cell death is a consequence of progressive DNA damage accumulation induced by 
simultaneous PARP and HR inhibition, we would expect it to emerge gradually over time. 
To confirm and better characterize the lethality observed in cultures treated with the compounds 
combination, we therefore considered it inappropriate to conduct a simple evaluation of the 
commonly used markers (e.g., caspase activation), since these can show very transient changes. 
Instead, we observed cell morphology and reaction to vital dyes after the 72 h treatment: BxPC3 
cells were stained with mixed DAPI and PI. The simultaneous use of these two dyes can 
demonstrate cell death and indicate the death pattern: DAPI is cell-permeable and shows nuclear 
morphology; healthy cells appear to display normal nuclear morphology in the absence of PI 
staining, since this dye is not cell-permeable. Cells undergoing apoptosis display nuclear 
condensation, which is indicated by increased DAPI staining. PI staining indicates compromised 
membrane integrity, which characterizes necrotic cells and late-apoptotic cells maintained in 
culture. 
The microscope pictures show that untreated BxPC3 cells display only a moderate DAPI staining 
of their nucleus. Nuclear DAPI staining is slightly increased in cells treated with ARN 24089 
alone but is strikingly bright only in cells treated with the ARN 24089+OLA combination. 
Furthermore, PI staining appeared only in these cultures, confirming the manifestation of 
synthetic lethality. The simultaneous marked staining of these cells with both dyes could indicate 
an apoptotic phenomenon followed by compromised membrane integrity because of cell 





As expected, the sustained and increased DNA damage observed in BxPC3 cells treated with the 
combination reproduced the desired mechanism of synthetic lethality. These results are also 
relevant given the mutated p53 status of BxPC3 cells, which should make them more resistant to 
mechanisms that induce cell death. [Figure 5.10]. 
 
 
Figure 5.10. After the 72 h treatment, BxPC3 cells were stained with vital dyes. As shown in the microscope 
pictures, the only culture displaying sharp evidence of cell death was that exposed to the combination of OLA+20 
μM ARN 24089, as demonstrated by PI nuclear staining. 
 
5.1.2.5 Viability Assay with Capan-1 and HK-2 
 
Finally, the antiproliferative effect of the ARN 24089+OLA combination was also studied on the 
HR- defective Capan-1 culture and on a non-neoplastic cell line derived from human kidney 
(HK-2). Moreover, to evaluate the antineoplastic potency of the ARN 24089+OLA association, 
we also calculated the combination index (CI) of the two compounds, using the procedure 
previously described in section 5.1.1.3. This evaluation was performed for all the three studied 
cell cultures: for BxPC-3 cells, the data reported in section 5.1.2.1 were used for the calculation 
of CI. Interestingly, in these cells the potency of the compound combination increased in parallel 
with the ARN 24089 dose, reaching a statistically significant difference from 0.8 at the 20 μM 
concentration. The effects observed when 20 μM ARN 24089 is combined with 10 μM OLA 
may thus indicate a synergism between the two compounds. 
In HK-2 cultures, no dose of ARN 24089 appeared to significantly increase the antiproliferative 
power of OLA (two-way ANOVA). In Capan-1 cells, the same statistical evaluation showed 
significantly increased antiproliferative effects for ARN 24089+OLA. However, in these cells, 
the CI did not show increasing potency of the compound combination with dose escalation. 
Moreover, at all tested doses, the value of CI was not significantly different from 1, which is the 
level measured in BxPC3 cells exposed to 10 μM ARN 24089, a dose that did not relevantly 
affect (≈10%) HR. This result further supports the idea that the over additive effects in the ARN 






Figure 5.11. (A) Antiproliferative effect caused by ARN 24089 and its association with OLA, measured in Capan-1 
cells (RAD51-BRCA2-dependent HR does not work in these cells) and in normal immortalized human renal cells 
(HK-2). The same procedures described for BxPC3 cells were used here. (B) Combination indexes of the ARN 
24089+OLA association measured in the three used cell lines, calculated according to the method previously 
described. For BxPC-3 cells, the data reported in the previous viability experiments were used. Data were analyzed 
using the column statistics and the one-sample t test of Prism 5 software. For BxPC-3 cells, this test showed a 
statistically significant difference from 0.8 for the combination of OLA and 20 μΜ ARN 24089. Values of <0.8 
indicate synergism between the two compounds. 
 
Within this project, our results proved that ARN 24089 synergizes with OLA in pancreatic 
cancer cells (BxPC3) and can reproduce the paradigm of synthetic lethality in combination. 
These effects were strictly related to the extent of HR inhibition in a dose-dependent trend. This 
is the most promising achievement of the current investigation and supports our working 






5.1.2.6 Project A final discussion (Zone II disruptors) 
 
The DNA repair and DNA damage response (DDR) pathways are suitable for the application of 
synthetic lethality as a novel anticancer therapeutic strategy. The classic example is the clinical 
application of PARP inhibitors in oncology patients with BRCA1/2 mutations. In this project, we 
proposed a new working hypothesis, dubbed “fully small-molecules-induced synthetic lethality”. 
This concept combines RAD51-BRCA2 disruptors with OLA in order to simultaneously impair 
two DNA repair pathways and trigger the synthetic lethality mechanism. 
Continuing our research line, we described a series of zone II RAD51-BRCA2 disruptors and 
ARN 24089 proved to be the most promising one out of all the tested compounds. ARN 24089 
bound to its target (RAD51) and inhibited the protein−protein interaction between RAD51 and 
BRCA2. Importantly, it synergized and reproduced the paradigm of synthetic lethality in 
combination with OLA in pancreatic cancer cells (BxPC3). These effects were strictly related to 
the extent of HR inhibition in a dose-dependent trend. These results prove that it is possible to 
trigger synthetic lethality using only small organic molecules. 
We note, however, that ARN 24089’s low solubility may affect its metabolic and 
pharmacokinetic profile, preventing it from being studied further in in vivo cancer models. 
Structural tuning is therefore required (and currently ongoing) to discover more drug-like 
efficient zone 2 disruptors. 
Interestingly, the observed synthetic lethality was triggered by tackling two biochemically 
different mechanisms: enzyme inhibition (PARP) and protein-protein disruption (RAD51-
BRCA2). This highlights how complex and diverse mechanisms of action can synergistically 
contribute to the same physiological and, in turn, pharmacological activity. 
In conclusion, we have further shown that synthetic lethality may be a suitable framework for 
discovering innovative anticancer therapies. We are confident that this novel concept will open 





















5.2 PROJECT B: INHIBITION OF HR ACTIVITY THROUGH THE USE OF LDH  
      INHIBITORS 
 
5.2.1 Metabolic characterization of cell cultures 
 
Neoplastic cells typically show highly increased rates of glucose uptake and glycolysis, after 
which the obtained pyruvate is converted to lactate by lactate dehydrogenase (LDH). The 
enhanced glucose metabolism was also found to promote other cancer-essential functions. 
Among these, the maintenance of a certain level of DNA integrity is a crucial function for 
supporting active proliferation. In literature, elevation of glycolysis was found to facilitate DNA 
repair and to confer cancer cells resistance to ionizing radiation. Considerable amounts of 
evidences also suggest that inhibition of glycolysis leads to compromised DNA repair, which is 
accompanied by energy depletion. Furthermore, increasing evidences suggest for lactate a role as 
signaling factor, involved in the modulation of gene expression. 
Based on the above exposed premises, the experiments reported in Project B were aimed at 
exploring a possible direct role of LDH in the DNA damage response (DDR). To do that, we 
used two different cell lines (named SW620 and BxPC3) who relied differently on LDH activity. 
To characterize the metabolic assets of SW620 and BxPC-3 cells we evaluated the expression of 
the two LDH isoforms (LDH-A and -B); furthermore, we assessed the levels of lactate and ATP 
in cultures exposed to oxamate (OXA), a well-studied LDH inhibitor, active in the millimolar 
range.  
The first experiment showed the relative levels of LDH-A and -B measured in the two cultures, 
normalized on the LDH-A expression of SW620 cells. Both cultures showed a clear prevalence 
of the B isoform of the enzyme [Figure 5.12, A]. The rate of lactate production measured in 
BxPC3 cells was 4-fold higher than that measured in SW620 cultures. Moreover, their ATP 
content dropped to a very low level when exposed to OXA, given at a dose as low as 10 mM. 
Opposite to BxPC-3 cultures, SW620 cells mainly base their energy metabolism on oxidative 
reactions since they appeared to maintain not significantly modified ATP levels even in the 
presence of 40 mM OXA, a dose which almost completely abolished lactate production [Figure 
5.12, B-C]. Contrary to the current opinion linking LDH-A to actively glycolytic metabolism 
[75], BxPC-3 cultures, in which the -A isoform of the enzyme was undetectable, showed an 
energy metabolism highly dependent on glycolytic reactions and resulted extremely susceptible 
to OXA.  
 
5.2.2 Cellular viability Assessed by CellTiter-Glo and Neutral Red 
 
The two different metabolic assets of these cell cultures were also confirmed by studying the 
effect of OXA on cells viability, assessed after a 24 h treatment by using two different 
procedures: Neutral Red assay (which gives an estimate of cell number) and CellTiter-Glo Assay 
(which measures ATP levels).  
Results showed that in SW620 cells the two procedures give superimposable results, and 




at 24 h. In these cultures, the ratio ATP / cell number was unchanged for all tested doses of OXA 
[Figure 5.13, B-C].  
When performed on BxPC-3 cultures, the same experiments showed that although LDH 
inhibition significantly affected the energy metabolism of these cells, no significantly reduction 
of viability was produced by 10-20 mM OXA. It is worth notice that, although viable, these 
cultures showed ATP levels reduced up to 30% [Figure 5.13, A-C]. 
 
 
Figure 5.12. (A) Evaluation of LDH-A and -B expression by real-time PCR. ND, not detectable. (B) Lactate and (C) 




Figure 5.13. Effect of OXA (10 mM-20 mM-40 mM-60 mM) on the viability of BxPC3(A) and SW620(B) cultures 
after 24h of treatment, assessed through the measure of ATP level or by evaluating cell number. In the case of 
BxPC-3 cells, the two procedures gave different results; when cell viability was assessed by evaluating cell number, 
no statistically significant effect appeared to be produced by 10 and 20 mM OXA at 24 h. Viability data were 
analyzed were analyzed by one-way ANOVA followed by  Dunnet ‘s post-test. *, p < 0.01 compared to control 
cultures. (C) Ratio ATP level / cell number, calculated from the results shown in (D,E). Data were analyzed one-







5.2.3 Study of homologous recombination in LDH-inhibited cells 
 
Both cultures were exposed to OXA given for 16 h at a dose causing significant inhibition of 
LDH enzymatic activity without affecting cell viability: 10-20 mM OXA was used for BxPC-3; 
40 mM for SW620 cultures. To test HR function in OXA-exposed cultures, we assessed:  
1. expression of genes involved in HR repair, 
2. plasmid recombination in transfected cells, 
3. extent of DNA damage caused by OLA, 
4. nuclear localization of RAD51 induced by a DNA damaging agent. 
 
5.2.3.1 Expression level of HR-related genes 
 
The expression level of a panel of genes was assessed by real-time PCR: BRCA1 and -2, RAD51 
and other genes involved in the HR mechanism (MRE11A; RAD50; NBN). Predictably, in ATP-
depleted BxPC-3 cells the expression of all examined genes appeared significantly lowered, with 
a variation ranging from -22% (BRCA1) to -50% (NBN) [Figure 5.14, A (white bars)].  
However, a statistically significant reduced expression of the same gene panel was also observed 
in SW620 cells, in which even higher effects were observed (-72% for BRCA2; -46% for 
RAD51) [Figure 5.14, B (white bars)].  
Studies report that the product of LDH reaction (lactate) has an impact on histone acetylation and 
gene expression [89-90]. For this reason, and in search of a possible explanation to the results 
observed in SW620 cells, we exposed these cultures to the same OXA treatment supplemented 
with 10 mM lactate. In line with published data, lactate supplementation was found to 
significantly reverse most of the changes observed in SW620 cells [Figure 5.14, B (dark bars)]. 
Unexpectedly, in spite of their ATP-lowered content, BxPC-3 cells were more responsive to the 
effects of this metabolite [Figure 5.14, A (dark bars)]. 
Taken together, the results suggest that LDH activity could be involved in controlling the 
expression of a crucial group of genes involved in HR. Depending on the cell context, the role of 
this enzyme in maintaining energy balance can contribute in causing the downregulated gene 
expression. However, a major impact appears to derive from the non-metabolic functions of the 





Figure 5.14. A group of key genes involved in the HR pathway was examined by real-time PCR in BxPC-3 (A) and 
SW620 cultures (B) exposed for 16 h to OXA. Data were evaluated using one-way ANOVA followed by Dunnet’s 
post-test. In BxPC-3 cells, a statistically significant reduced expression was found for all examined genes, with the 
exception of BRCA1; p values ranged from <0.05 to <0.01. In the case of SW620 cells, a statistically significant 
difference compared to control cultures was observed for all genes, with p<0.01. The graphs also show the effect of 
lactate supplementation on gene expression (grey bars). In spite of their ATP-lowered content, BxPC-3 cells proved 
to be very responsive to this metabolite, which completely reversed all the OXA-driven effects. In SW620 cells 
lactate was able to significantly reverse the effects of LDH inhibition in 3 out of 6 genes. (*), p < 0.05; (**) < 0.01 
(**); (***) < 0.001. 
 
5.2.3.2 Evaluation of plasmid recombination in OXA treated cells 
 
We applied to OXA-exposed cultures a commercially available assay specifically designed to 
study the co-transformation in bacterial cells of two plasmids bearing homology sequences. The 
provided couple of plasmids can be also transfected into mammalian cells. In these cells, they 
recombinate in episomal form using the enzymatic machinery of the host and produce a real-time 
PCR detectable sequence. In line with the results of the previous experiments, in BxPC-3 cells 
the obtained recombination product appeared to be significantly decreased. On the contrary, in 
SW620 cultures higher rates of plasmid recombination were detected [Figure 5.15].  
To explain this finding, we hypothesized that in these cultures alternative pathways of DNA 
recombination can take place when HR genes are down regulated. These pathways have also 
been described as more rapid and, consequently, more error prone when compared to HR.  
We measured the expression of a list of genes involved in alternative recombination pathways: 
classical non-homologous end joining (NHEJ) and alternative end joining (EJ). The expression 
of these genes was examined in both the OXA-treated cultures. Predictably, in ATP depleted 
BxPC-3 cells 5 out of 10 examined genes involved in NHEJ and/or alternative EJ were found to 
be downregulated. On the contrary, in SW620 cells a reduced expression was detected only in 
two genes, suggesting that in these cultures the alternative pathways could work and their prompt 






Figure 5.15. Episomal plasmid recombination assessed in the two cell lines by using a commercially available 
assay. For explanation, see text. In BxPC-3 cells, a statistically significant reduction was observed for both OXA 
doses, with p < 0.05 (*) (ANOVA). 
 
Table 5.3. Expression of genes involved in alternative pathways to homologous recombination repair. Changes 






5.2.3.3 γ-H2AX immunoblotting in OXA/OLA treated cells 
 
For this experiment, cells were exposed for 16 h to OXA administered singularly or in 
association with OLA (10 µM). This OLA dose was chosen on the basis of results obtained by 
studying the association of OLA with different inhibitors of HR (Project A). As well 
documented, in conditions of compromised HR repair (e.g. in BRCA1/2 defective cancer cells) 
PARP inhibition results in increased DNA damage signatures, which can be evaluated by 
assessing γ-H2AX levels, a commonly used DNA damage indicator. This effect was entirely 
reproduced in SW620 cells exposed to the association of the two compounds. In these cultures, 
OLA caused enhanced γ-H2AX levels, but the simultaneous exposure to OXA was found to 
significantly increase the effects of PARP inhibition, giving a proof compromised HR in LDH-
inhibited cells [Figure 5.16, A]. 
On the contrary, and in spite of the results obtained in the two previous assays, LDH inhibition 
did not appear to induce significantly increased DNA damage in OLA-exposed BxPC-3 cells. In 
our opinion, this result can be easily explained considering that ATP deprivation of LDH-
inhibited BxPC-3 cells is expected to impact on phosphorylation-mediated signaling and to 
reduce cell competence in managing DNA damage [Figure 5.16, B]. 
 
Figure 5.16. DNA damage was assessed by an immunoblotting evaluation of H2AX histone phosphorylation (γ-
H2AX). The experiment was performed in both cell cultures exposed for 16 h to OXA and 10 µM OLA, administered 
separately or in association. 10 and 40 mM OXA were used in BxPC-3 and SW620 cells, respectively. The bar 
graphs show a densitometric estimation of γH2AX bands, normalized on Actin levels. In the case of SW620 cells, 
OLA was found to significantly increase γH2AX level; the extent of DNA damage was further raised by the 
association OXA/OLA (A). In BxPC-3 cells a slight, but statistically significant increased level of γH2AX was 
observed in all treated samples; however, in these cells OXA did not caused increased DNA damage in OLA-
exposed cultures (B). *, p < 0.05, compared to control cells. #, p < 0.05, compared to OLA treated cells (one-way 




5.2.3.4 Evaluation of RAD51 nuclear translocation upon CPL treatment 
 
A further proof of compromised HR in LDH-inhibited cells was obtained by studying RAD51 
nuclear translocation following a short exposure to cisplatin (CPL), a chemotherapeutic agent 
causing direct DNA damage. BRCA2-mediated translocation of RAD51 in cell nuclei is one of 
the earliest events at the onset of HR repair. The nuclear localization of RAD51 can be 
evidenced by an immunofluorescence staining of this protein in CPL treated cells. In this 
experiment, CPL was found to significantly increase RAD51 immunolabeling in the nuclei of 
both BxPC-3 and SW620 cultures, with a p value < 0.05 and 0.01, respectively. When 
administered to untreated cells, OXA did not modify the nuclear immunolabeling of RAD51; on 
the contrary, when administered to CPL-probed cells, the LDH inhibitor appeared to reduce 
RAD51 immunolabeling in nuclei to a level not dissimilar from that of untreated cells [Figure 
5.17]. 
 
Figure 5.17. Cell cultures were probed with 50 µM CPL for 1.5 h and maintained in the presence of OXA for 24 h. 
The data reported in the bar graphs were statistically evaluated by one-way ANOVA followed by Dunnet’s post-test. 
Asterisks indicate a significant difference compared to untreated cells (CTR), with p < 0.05 (*) and p < 0.01 (**). 
 
Taking these data together, in both BxPC-3 and SW620 cultures three of the four applied 
procedures to evidence inhibited HR after LDH inhibition gave coherent results. In both cultures, 
we observed a single inconsistency: in OLA-exposed BxPC-3 cultures, OXA treatment did not 
result in increased DNA damage [Figure 5.16, B]. In OXA-treated SW620 cells, plasmid 
recombination was found to proceed at even higher rates [Figure 5.15]. Since both these 
discrepancies can be easily explained, the obtained results overall suggest that LDH inhibition 





5.2.4 Cell viability and death in combination experiments with OXA and OLA 
 
After proving that LDH inhibition could impair HR, we wanted to verify if it could also increase 
the effect of OLA in BRCA-proficient cells. We performed various combination experiments 
with OXA and OLA, aimed at assessing cell viability and death caused by the compounds’ 
association. The obtained data were statistically evaluated by two-way ANOVA using the OLA 
doses and OXA supplementation as variables. 
In BxPC-3 cells, the potency of the compounds’ association increased in parallel with the doses 
of OLA and OXA, and this effect was observed in the study of both cell viability and death. In 
both experiments, the statistical evaluation showed a strongly significant interaction between the 
two compounds, with p < 0.0001.  
 
Figure 5.18. Cell viability was studied by applying the Neutral Red assay in BxPC-3 (A) and in SW620 (B) cultures 
treated for the indicated time with OXA and OLA, administered singularly or in combination. Cell death was 
assessed by using the CellToxTM Green Cytotoxicity Assay (Promega), following the instruction of the manufacturer. 
Data were statistically analyzed by applying the two-way ANOVA, using OLA and OXA supplementation as 
variables. ****, p < 0.0001, when compared to OLA administered as a single treatment (Bonferroni’s post-test). 
The viability data reported in (A) and (B) were also used for an estimation of the C.I. of the OXA/OLA association. 
A detailed explanation of the obtained results is given in the text. 
 
Interestingly, the heavily lethal effects observed in these cells at 48 h cannot be simply ascribed 
to the impaired energy metabolism caused by LDH inhibition, since they appeared only in 
cultures treated with the compounds’ association [Figure 5.18, A].  
In studying cell viability of the SW620 cultures a statistically significant effect caused by OXA 
and OLA was observed, both at 48 and at 96 h, with p values ranging from 0.0002 to < 0.0001. 
However, in this case the statistical analysis indicated no interaction between the two 




supplementation is similar for both the tested doses of OLA. Although in SW620 cultures the 
evidence of cell death caused by the association OLA/OXA was quite lower than that observed 
in BxPC-3 cells, the interaction between the two compounds on this parameter resulted 
statistically significant, with p = 0.039 at 48 h and p < 0.0001 at 96 h [Figure 5.18, B].  
These results suggest that the increased potency of the compounds’ association is mainly 
evidenced when considering its lethal effects, even though the entity of these effects can variate 
depending on the cell context. Notably, the induction of alternative recombination pathways can 
be a crucial factor driving lethality in cells with inhibited HR and PARP function and, as 
described above, in OXA-treated SW620 cells these pathways seem to be operative.  
The potency of the OXA/OLA association was also evaluated by applying to the data of cell 
viability the procedure to assess the combination index (CI) between an enzyme inhibitor and 
antineoplastic agents. This calculation procedure was already used to evaluate the potency of the 
association OLA / RAD51-BRCA2 disruptors [5.1.1.3].   
When applied to the overall viability data obtained in BxPC-3 cells, this procedure returned a CI 
= 0.35, with a 95% confidence interval ranging from 0.12 to 0.58, clearly indicating for these 
cells the occurrence of synergism between the two compounds. In the case of SW620 cultures, a 
CI = 0.84 was measured, with a 95% confidence interval ranging from 0.77 to 0.91. Therefore, in 
this case the interaction between OXA and OLA appeared to be characterized by additive effects. 
Taken together, the results are in total agreement with the indications given by the two-way 
ANOVA test. 
 
5.2.5 Cell death evaluation in combination experiments with OXA and OLA 
 
We designed a new set of experiments aimed at better defining the cell death pattern observed in 
the two cell cultures. In these experiments, the two cell cultures were exposed to the OLA/OXA 
association for 48 h and then treated with vital dyes (DAPI and PI) without a fixation step in 
paraformaldehyde. The simultaneous use of these two dyes can demonstrate cell death, also 
giving indication on the death pattern. DAPI is cell-permeable and evidences nuclear 
morphology; healthy cells appear to display normal nuclear morphology in the absence of PI 
staining, since this dye is not cell-permeable. Cells undergoing apoptosis display nuclear 
condensation, which is indicated by increased DAPI staining. PI staining indicates compromised 
membrane integrity, which characterizes necrotic cells and late-apoptotic cells maintained in 
culture.  
The DAPI/PI staining procedure confirmed the massive death of BxPC-3 cells already observed 
at 48 h in the previous set of experiments. The bright PI staining of these cultures suggest loss of 
membrane integrity, as can be expected in cells with compromised energy metabolism. SW620 
results were also in agreement with the previously obtained data, showing a low level of cell 
death at 48 h [Figure 5.19].  
For this reason, cell death was further investigated by an immunoblotting evaluation of the 
BAX/BCL2 ratio, which was performed in both cell lines. Although BxPC-3 and SW620 cells 
appeared to express different BAX and BCL2 levels, the densitometric calculation of the ratio 




In both cultures, apoptosis appeared to be significantly increased (compared to control cells) only 
because of the combined OLA/OXA treatment. [Figure 5.20]. 
Those findings suggested that the molecular signatures of apoptosis were evident in both cell 
cultures at a very similar level. Furthermore, they indirectly confirmed that the reduced ATP 
availability of OXA-exposed BxPC-3 cells can be the key factor in generating the membrane 
damage and the consequent heavy lethality observed in these cultures.   
 
 
Figure 5.19. Assessment of cell death with vital dyes. In BxPC-3 cells death appeared to be sharply evident. The 
observed staining pattern is compatible with apoptosis (increased DAPI staining suggesting nuclear condensation) 
followed by damaging of membranes (deep PI staining). In SW620 cultures PI staining pattern appeared pale and 
limited to some areas of the microscope slide. For this reason, an additional assay was applied to these cells. 
 
 
Figure 5.20. Assessment of apoptosis at the molecular level, through the immunoblotting evaluation of BAX/BCL2 
ratio in BxPC3 (A) and SW620 (B) cells. As shown in the bar graph, only cultures treated with the compounds’ 
association showed a statistically significant difference in their BAX/BCL2 ratio when compared with untreated 




5.2.6 Project B final discussion 
 
LDH is a major player in cancer cell metabolism. The data of our preliminary investigation 
suggested an LDH-mediated control on HR, the most critical DDR pathway for restoring 
chromosome integrity and, hence, potentially affecting cell response to chemotherapeutic agents. 
Our results indicate that this control could be exerted by simply assuring the adequate energy 
supply needed to the DDR and/or by regulating the expression level of genes involved in DNA 
repair. Although preliminary, they highlight a complex relationship between metabolic reactions 
and the control of DNA integrity. Furthermore, they offer a mechanistic explanation to several 
published reports showing increased cell response to antineoplastic agents after LDH inhibition 
or knockdown. 
In latest years, in the attempt of developing innovative anticancer strategies, treatments with 
small molecules able to hinder DNA repair have been proposed. The rationale underlying this 
therapeutic approach lies in the genetic instability of cancer cells, which makes them more 
dependent on DNA repair mechanisms, compared to healthy cells. PARP inhibitors (e.g. OLA) 
are a well-known example of antineoplastic drugs targeting the DDR. However, clinical 
experience with these compounds showed successful therapeutic results only on cancer forms 
characterized by HR deficiency, which cannot compensate for the inhibited PARP function. To 
broaden the use of PARP inhibitors, the association of OLA with conventionally used 
chemotherapeutics was also proposed, with the aim to obtain enhanced therapeutic power. 
Furthermore, the effect of this drug was tested in cancer contexts characterized by different DNA 
repair deficiencies, such as colon cancer with microsatellite instability. However, these 
approaches were often found to produce increased systemic toxicity; in addition, the potential 
increased risk of incurring in secondary malignancies, after the successful control of the primary 
tumor should be considered.  
The findings described in this thesis suggest a possible use of LDH inhibitors to extend the use 
of OLA to HR proficient tumor forms. Recently, the first LDH inhibitor potentially active in 
vivo has been identified. In the used animal model, the only observed toxic effect that could 
potentially narrow the therapeutic window of this novel compound was found to be hemolysis, 
presumably linked to the metabolic inhibition of red blood cells. Taken together, these data 
suggest a combination of OLA with LDH inhibitors as a worthwhile therapeutic attempt to 



















In recent years, innovative anticancer treatments have relied on targeted therapies to improve 
drug efficacy and reduce side effects. The use of novel molecules or antibodies that could 
precisely target a single protein has increased the chances of survival of many patients. 
One of these innovative treatments involves the use of small drugs to induce synthetic lethality in 
tumors with specific genetic mutations: the main example is the use of PARP inhibitors, such as 
OLA, in tumors with BRCA1/2 mutations. The effectiveness of this treatment has been 
demonstrated in ovarian cancer (for which OLA was originally approved), and in clinical trials in 
breast and pancreatic cancers.  
In this project, we report a new approach to the synthetic lethality treatments dubbed “fully 
small-molecule induced synthetic lethality”. This paradigm was based on the observation that, by 
using a small organic molecule capable of impairing the HR mechanism, it is possible to mimic 
the effect of BRCA2 germline mutations and widen the population of patients eligible for 
treatment with OLA and other PARP inhibitors. 
 
In our experiments, we impaired HR mechanism using a direct and an indirect approach and we 
obtained meaningful results with both of them. 
In project A, ARN 24089 could bind to its target (RAD51) and inhibit the protein−protein 
interaction between RAD51 and BRCA2. Importantly, it synergizes and reproduces the paradigm 
of synthetic lethality in combination with OLA in pancreatic cancer cells (BxPC3).   
In project B, our data suggest an LDH-mediated control on HR, the most critical DDR pathway 
for restoring chromosome integrity. Although preliminary, they highlight a complex relationship 
between metabolic reactions and the control of DNA integrity. Furthermore, LDH inhibition also 
managed to increase the efficiency of OLA in all the tested cell lines and triggered the synthetic 
lethality mechanism.  
 
In conclusion, these projects demonstrated that in some cases it is possible to apply an anticancer 
therapy (in our case, synthetic lethality therapies) to a wider type of cancers by utilizing small 
molecules that mimic a specific cellular environment. This could open up new possibilities for 
the treatment of cancers with high mortality rates, such as pancreatic adenocarcinoma, which is 
particularly therapy resistant.  
We believe that the “fully small-molecule induced synthetic lethality” will prove to be useful 
even with other synthetic lethality gene pairs and will be able to meet the medical needs in the 
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